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 Over the past several decades the prevalence of obesity and asthma have 
increased in a parallel fashion. Recent studies reported a positive relationship between the 
two disorders that may in fact be causal. Although the link between obesity and asthma 
has become widely recognized, the underlying pathophysiological connection is not 
elucidated. Increased markers of inflammatory and oxidative stress are present in obesity 
and asthma suggesting the link is immunological. The systemic inflammation observed in 
obesity may potentially initiate adverse affects in the airways. Previous studies have 
shown that consumption of dairy foods (rich in calcium and leucine) suppress 1,25-
dihydroxycholecalciferol (calcitriol) resulting in decreased inflammatory stress 
associated with excess adiposity. Additionally, adipocyte leucine treatment was reported 
to decrease pro-inflammatory TNFα and increase anti-inflammatory adiponectin 
cytokines, which have been implicated in asthmatic disease. Consequently, we sought to 
determine if correcting the imbalance of adipocyte inflammatory cytokine secretion via 
calcium and leucine treatment would have a functional effect on airway inflammation. 
We demonstrated that conditioned medium collected adipocytes  (ACM) treated with 
leucine for 48hrs significantly reduced monocyte-airway smooth muscle adhesion, lung 
endothelial cell ICAM-1 adhesion molecule expression, and polymorphonuclear (PMN) 
cell CD11b expression in vitro compared to control, while calcitriol exerted the opposite 
effects. Furthermore, these findings were extended to an established murine model of 
asthma. Female BALB/c mice were sensitized and challenged with chicken egg albumin 
(OVA) to induce airway inflammation. Animals were fed a high fat diet with no 
supplementation, high calcium (1.2%), leucine (200% normal levels), or a diet with a 
 v
combination of calcium (1.2%) and leucine (200% normal levels). We found that the 
combined high calcium and leucine supplemented high fat diet animals had significantly 
less eosinophils in collected bronchoalveolar lavage fluid (BALF) compared to control 
diet mice. These data suggest that calcium and leucine may have potential therapeutic 
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Asthma prevalence has increased in industrialized nations over the past several 
decades (1). The increase in asthma diagnosis has been observed in all ages, genders, and 
racial groups (1). Over 300 million people suffer from asthma globally with over 25 
million people living with asthma in the United States alone (2-5). The obesity epidemic 
and asthma have grown in a parallel fashion and there is an increasing body of evidence 
to suggest a positive relationship between the two disorders (6,7). Prospective studies 
have shown that increasing BMI correlates with an increased risk of asthma development 
while weight loss improves the course of the illness (8,9). Obesity is acknowledged as a 
predisposing factor for asthma development. However, the underlying pathophysiological 
connection remains elusive. As both asthma and obesity share many of the same 
inflammatory cytokines and oxidative stress markers a likely connection may be 
immunological (10-12). The chronic low-grade systemic inflammation and oxidative 
stress may work synergistically to adversely modify the airways. The balance of 
inflammatory and anti-inflammatory cytokines secreted by adipose tissue is altered by 
oxidative stress (13). The increase in reactive oxygen species (ROS) suppresses adipose 
tissue expression of adiponectin and increases expression of inflammatory factors, 
including TNFα, while suppression of ROS exerts the opposite effect (13). Mitochondrial 
uncoupling status and cytosolic Ca
2+
 signaling, both of which are regulated by calcitriol 
(vitamin D3) modulate adipocyte ROS production (14-16). Calcitriol suppresses the 
expression of adipocyte uncoupling protein 2 (UCP2), resulting in greater mitochondrial 
membrane potential, and stimulation of cytosolic Ca
2+
 signaling, both of which lead to 
increased ROS production (14-17). We have recently shown physiological concentrations 
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of calcitriol (100pm-10nM) similar to levels observed in calcium deficiency stimulated 
the expression and secretion of inflammatory cytokines, including TNFα, while inhibiting 
adiponectin expression and secretion (14-17). These concentrations of calcitriol stimulate 
ROS production in both murine and human adipocytes (14-17). Further, we have shown 
calcitriol to exert comparable effects in macrophages and to stimulate macrophage-
adipocyte cross talk and inflammatory response in co-culture (17).  
Consequently, we evaluated the ability of dietary calcium-induced suppression of 
circulating calcitriol to attenuate oxidative and inflammatory stress and found significant, 
substantial suppression of both adipose tissue and systemic oxidative and inflammatory 
stress in a mouse model (14, 18). These findings were extended to a randomized, blinded 
cross over clinical trial in overweight and obese subjects where it was found that 
suppressing circulating calcitriol with a calcium-rich diet suppresses systemic oxidative 
stress by ~20%, reducing TNF-α and increased adiponectin by 20% (p<0.002)(18).  
Recent studies support a role for leucine in attenuating oxidative and inflammatory stress 
has been supported  (19,20). We have found 0.5 mM leucine (comparable to levels 
achieved following a leucine-rich meal) to stimulate mitochondrial biogenesis in both 
adipocytes and muscle cells, with an associated increase in oxygen consumption and fatty 
acid oxidation in both cell types (20). This increase in energy utilization reduces the 
oxidative and inflammatory stress that otherwise results from nutrient overload and 
obesity. 
The purpose of this work was to determine if leucine and calcium treatment have 
a functional effect on the obesity associated airway inflammatory process using both in 
vitro and in vivo models.  
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Asthma is an inflammatory disease of the airways affecting more than 300 million 
people worldwide
1
 with over 25 million living in the United States in 2010
2-4
. Urbanized 
nations such as the US have reported increases in asthma prevalence among all racial 
groups, ages, and genders over the past thirty years 
5
. As the leading childhood chronic 
illness, asthma affects more than ten million American adolescents and children
6
. By the 
year 2025, the number of childhood asthmatics in the US is expected to exceed 100 
million
7
. Although modern treatment has helped lower mortality
8
,over 250,000 people 
die annually from asthma related symptoms
9
. Asthma can affect people of any age. The 
term ‘phenotype’ has been initially used to describe the heterogeneity in asthmatic 
manifestations
10
. Asthmatic phenotypes/endotypes are characterized based on criteria 
such as: presence of allergy, severity, pathology (eosinophilic, noneosinophilic) and age 
of onset among other factors
11-17
. Endotype is a relatively new concept in asthma 
classification
18
. The term was introduced to specially describe subphenotypes in asthma 
that include distinctive or unique pathological or functional mechanism such as aspirin-
sensitive asthma, early onset allergic asthma, neutrophilic and obesity- related, Th2 
associated, severe late onset eosinophilic, non Th2 associated and bronchopulmonary 
mycosis
13
. Collection of adequate laboratory and clinical data on each asthmatic patient is 
needed before an appropriate definition of specific phenotypes can be determined
18
. 
Therefore, characterizations of all the distinct asthmatic phenotypes and pathologies have 
yet to be fully elucidated.  
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2.1.2 Disease Description 
Many different cell types participate in the pathology of asthma mast cells and 
eosinophils are critical in the airway inflammatory process while leukotrienes, cytokines, 
histamine mediators and T lymphocytes are also involved
10
. Pathologies such as airway 
inflammation as well as airway hyper-responsiveness (AHR) associated with reversible 
airflow obstruction are traditional attributes of asthmatic disease
19
. Classic clinical 
symptoms of asthma patients are recurrent episodes of wheeze, shortness of breath, and 
coughing due to abnormalities in the airways
2
. Several other symptoms such as bronchial 
hyper-responsiveness and airway obstruction typically associated with asthma are also 
pathologically linked to other disorders such as obstructive sleep apnea, obesity, 
stressors, reflux or atopy
20
. Asthma attacks (acute exacerbations) pose the biggest threat 
to the asthmatic patient. Exacerbations are episodes of airway obstruction (chest 
tightness, shortness of breath, coughing, and wheezing) that may result in loss of lung 
function or death
21
. Asthmatics experience these recurrent episodes of airflow 
obstruction, airway hyper-responsiveness and inflammation in response to irritants, 
allergens, cold air, or exercise exposure
22
. Symptom control is crucial to improving the 
severity and frequency of life threatening acute exacerbations. Defining the underlying 





The underlying pathophysiological mechanism of asthmatic disease involves a 
dysfunctional multisystem response including airway epithelium, airway smooth muscle, 
and circulatory system
22
. Histological changes involve epithelial damage, thickening of 
 9 
the basement membrane, mucus production and airway smooth muscle (ASM) 
thickening.
22,23
 The frontline defense for healthy airways against allergens or stimuli in 
the environment is the airway epithelium
24
. Asthmatics however, suffer from incomplete 
formation of tight junctions in the airway epithelium that are defective in preventing 
allergen infiltration into the airway tissue
24
. Damage to epithelium and composing 
epithelial cells is a result of chronic airway inflammation
20
. This airway inflammation is a 
result of leukocyte infiltration and subsequent cytokine secretion. Eosinophils are one of 
the first major cell types recruited to sites eliciting an inflammatory response
25-27
. Asthma 
development and progression are affected by eosinophil secretion of lipid mediators, 
reactive oxygen species (ROS), cytokines, and toxic granule proteins
28
. Eosinophils play 
an active role in asthmatic airway remodeling through several mechanisms. Interactions 
with epithelial and mesenchymal cells, release of cationic proteins, cytokines, and 
eosinophil-derived TGF-β are all contributors to eosinophil influenced airway 
remodeling
29-31
. Necrotic airway epithelial cell cellular debris, mucin produced by goblet 
cells, eosinophils, lymphocytes, neutrophils, and plasma protein exudate make up the 
composition of mucous
32-34
. Over the past several years there has been an emerging 
interest in asthma airway remodeling mechanisms
35
. Remodeling and inflammatory 
processes work interdependently to induce structural changes in the asthmatic airway
36
. 
Airway remodeling has been suggested to be a consequence of injured airway epithelial 
cells that work as an incessant stimulus for the process
35
. Reactive oxygen species (ROS) 
generated from resident inflammatory cells in the lung are key contributors to asthmatic 
pathophysiology
37
. Diminished β-adrenergic receptor response, airway 
hyperresponsiveness, elevated vascular permeability, mucus hypersecretion, secretion of 
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neuropeptides, and release of chemoattractants can all result from the production of 
reactive oxygen species 
37-42
.  Numerous enzymatic and non-enzymatic antioxidants work 
to protect the lungs and blood from ROS generated from mitochondria as a consequence 
of regular cellular metabolism
43
. Obesity increases systemic oxidative stress which alters 
adipokine secretion by decreasing anti-inflammatory adiponectin while increasing 
inflammatory cytokine secretion
44-46
. Oxidants induce the inflammatory process while 
antioxidants reduce oxidative stress and ameliorate adverse adipokine secretion
44-46
. It 
remains unclear which of these aspects of pathogenesis is the initial stimulus for disease 
manifestation. Traditionally, the classic asthmatic phenotype presents high IgE levels 
accompanying eosinophilia in the airways
20
.   
2.1.4 Airway Inflammation 
  Asthmatics suffer from chronic airway inflammation
20
. Inflammatory cells, such 
as leukocytes, are responsible for secretion of potent chemical mediators that initiate 
inflammation in the airways
20
. Classically, T helper type 2 (Th2) lymphocytes were 
thought to be solely responsible for asthma initation
20
. First, antigen presenting cells such 
as dendritic cells (DCs) would take up allergens and present them to naïve T helper cell 
lymphocytes
20
.  Allergens such as pollens, house dust mites, animal dander, fungi are 
common inhaled stimulants that can be responsible for asthma sensitization
20
. As a 
consequence of sensitization allergen specific Th2 cell production is initiated
20
. 
Proliferation of Th2 cells stimulated by inhaled allergens increase production and release 
of cytokines such as interleukin (IL)-4, IL-5, and IL-13, which contributes to asthma 
development
20
. Modern characterization has incorporated Th9 and Th17 lymphocytes as 
well in disease modulation
20
. It has been reported that airway inflammation can be 
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induced by Th17 produced IL-22, IL-17A, and IL-17F
20
. Additionally, IL-17A enhances 
the contractility of airway smooth muscle cells
20
. 
Histological changes involve epithelial damage, basement membrane thickening, mucus 
production and airway smooth muscle (ASM) thickening
22,23
. Although it is not clear 
which of these factors is the most important, airway smooth muscle is an essential 
element of acute airway narrowing
23
. The increased smooth muscle mass in different 
individuals may be caused by hypertrophy and/or hyperplasia
23
. However, since 
mammalian cells must undergo cell enlargement prior to mitosis, cell growth and 
increased contractile protein expression is common to both
47
. Multiple signaling 
pathways and growth factors are involved in regulating ASM proliferation. These include 
the phosphaditylinositol 3-kinase (PI3K) pathway, the extracellular single-regulated 
kinase (ERK) pathway and peptides such as platelet-derived growth factor (PDGF) and 
epidermal growth factor (EGF)
23
.  
Airway inflammation by leukocyte infiltration into airways is one of the staple 
characteristics of asthmatic disease
26
. Polymorphonuclear cells (PMNs) leukocytes 
include neutrophils, eosinophils, and basophils
30
. PMN subtypes have diverse roles in 
immunological responses. Eosinophils, neutrophils, and mononuclear leukocytes such as 
monocytes have been implicated in airway diseases
27
. The β2-integrin CD11b is 
expressed continuously on multiple leukocyte sub populations including eosinophils, 
neutrophils, and monocytes
27
. After stimulation with a cytokine or other mediator of 
stress, leukocytes are activated and increase levels of CD11b integrin expression on the 
cell surface
27
. This increased expression is needed for proper guidance and attachment to 
resident cell types at the site of inflammation
27
. Upon reaching the site of inflammation 
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via chemotactic guidance, eosinophils, neutrophils, and monocytes begin rolling on P and 
E selectins expressed on endothelial cells
27
. Before infiltration is initiated the leukocyte 
anchors via adhesion molecules
27
. 
Intracellular adhesion molecule (ICAM-1) is present on vascular and pulmonary 
endothelial cells as well as smooth muscle cells
48
. Upon injury or stimulation from stress 
the expression of ICAM-1 surpasses normal levels and awaits arrival and attachment of 
leukocytes
48
. Adhesion molecules such as ICAM-1 anchors the leukocyte and guides 
infiltration into tissue
48
. Once leukocytes are present in the tissue, cytokine and 
chemokine secretion is amplified
48
. The newly present mediators of inflammation recruits 
more leukocytes and initiates remodeling as a consequence of ongoing inflammation
48
. 
2.1.5 Cytokines in Atopic Asthma 
The staple cytokines in classical asthma are encoded on chromosome 5q31 in the 
IL-4 gene cluster
50
. Cytokines encoded on the gene cluster such as IL-4, IL-5, IL-13, IL-9 
as well as granulocyte colony stimulating factor (GM-CSF) contribute to asthma is 
different ways
50
. IL-4 is a Th2-cell-associated cytokine that promotes increased 
expression of adhesion molecules, B-cell isotype switching, facilitates goblet cell 
metaplasia, and airway hyperresponsiveness (AHR) and stimulates eotaxin secretion
20,51
. 
2.1.6 Asthma Disparities 
Although the prevalence of asthma has grown in urbanized nations in the past 
several decades among all populations
52
, the largest percentage increase is observed in 
children
3
. Traditionally thought of as an allergic disease it seems fitting that children with 
allergies are more likely to develop asthma
53,54
. However, recent findings have reported 
non-allergy related asthma in a large population of childhood patients
53-55
. These types of 
 13




Although more obvious in obese women compared to obese men
56
, there is an 
increasing body of evidence for an association between asthma and obesity
57-59
. Several 
cross-sectional studies have found obesity to be a predisposing factor in both children and 
adults for asthma onset
60
. The underlying mechanism connecting obesity and asthma is a 
controversial research topic. One theory proposes the increase in inflammatory and 
oxidative stress observed in obesity to synergistically harm the airways
61
. Increased pro-
inflammatory cytokine production from excess adipose tissue observed in obesity has 
been associated with asthma
61
. It has also been suggested that the adipokine-asthma 
association is age and sex dependent as the link is more pronounced in premenopausal 
women, prepubertal boys, and peripubertal girls
62,63
. Perhaps there is a hormone ratio 
guiding the T-cell responses in addition to excess adiposity resulting in distinguished 
phenotypes
64
. Increased estrogen levels as experienced in phases of sexual maturity and 
increased adiposity greatly influence immunological responses and may amplify obesity 
related pro-inflammatory cytokine secretion
64
. A combination of symptoms, the degree of 
bronchial obstruction, dose of inhaled corticosteroids needed for asthma control, intensity 
of treatment, and inflammatory markers are criteria used to define severe asthma
58
. 
Frequent exacerbations in severe asthma are associated with comorbidities such as 







2.1.7 Current Asthma Therapies  
Albeit pathological descriptions of asthmatic disease give insight into the 
established mechanistic aspects of the disease, they are not appropriate for clinical 
purposes
66
. More practical in primary care setting breathlessness, coughing, wheezing, 
and tightening of the chest define the disease, which fluctuates over time in intensity, 
frequency and occurrence
66




There are several medications available to control asthma: inhaled 
glucocorticosteroids, leukotriene modifiers, long-acting inhaled β2-agonists (LABA)s in 
combination with glucocorticosteriods, systemic glucocorticosteroids, theophylline, 
cromones, and anti-IgE. Reliever medications which include rapid acting inhaled β2-
agonists, systemic glucocorticosteroids, anti-cholinergics, theophylline, and short-acting 
oral β2-agonists
67
. Most commonly, asthma is treated by inhaled corticosteroids (ICS) as 
well as bronchodilators to improve quality of life and alleviate the frequency of 
symptoms
67
. There are subsets of asthmatics that do not respond well to standardized 
treatments
67
. Particularly, asthmatics that are also defined as obese seem to have a 
treatment refractory phenotype
67
. A decreased response to inhaled corticosteroids used in 
asthma management has been observed in overweight or obese children
67
. Severe 
asthmatics who are of normal weight are significantly more likely to exhibit optimal 
asthma control compared to overweight subjects
68
. Further, the optimal control state was 
completely missing in severe asthmatics that were obese
68
. From these observations it 
appears that severe asthmatic patients with good nutritional status seem to correlate with 
better “controlled” pulmonary disease management
68
. These findings agree with previous 
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studies that have shown that normal weight asthmatics have better disease control than 
obese patients
69
. The recently observed neutrophil rich airway inflammation of obese 




2.2 Adipose Tissue 
2.2.1 Adipocytes 
Adipose tissue is found in two major types throughout the human body, the first 
and most abundant in adults is white adipose tissue (WAT) the second is more prominent 
in infants and is termed brown adipose tissue (BAT)
72
. White adipocytes are filled with a 
single large lipid droplet and are spherical
72
. Adipocytes interact with the heart, liver, and 
skeletal muscle as a very important component of metabolic processes
73
. After a meal 
rich in fat, adipocytes will store TAG absorbed from the intestinal tract (chylomicrons) or 
the liver (VLDL) until needed for fuel
73
. When additional fuel is needed for physiological 
processes TAGs will by hydrolyzed to release free fatty acids by adipocyte lipases
73
. 
Adipose tissue mass depends on the number of adipocytes and volume of each cell
74
. The 
volume of adipocytes is determined by the removal and storage of TAGs
75
. Lipid 
turnover or rate of TAG removal refers to the hydrolysis of TAGs (lipolysis) to remove 
lipid stores from adipocytes, which is then followed by oxidation that is an irreversible 
process
76
. Obesity (excess adipose tissue) alters rate of lipid turnover and hence decreases 
the removal rate of TAGs
76
.   
2.2.2 Obesity  
Obesity is a global epidemic with extremely expensive healthcare 
consequences
77,78
. Cancer, cardiovascular disease, type II diabetes, and asthma are among 
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many consequences of obesity
73
. Obesity is determined by a body mass index (BMI) of ≥ 





Currently, in the United States over 30% of adult men and women are considered obese 
and 35% are overweight (BMI >25)
72
. A BMI below 25 is considered normal; 25-29.9 is 
overweight and ≥30 is characterized as obese
72
. Obesity is a consequence of consistent 
intake of more calories than are expended resulting in unused calories and subsequent 
excess adiposity
72
. The excess of dietary calories can be used in several ways. First, 
excess calories can be utilized by treating them as “waste” using them as fuel for 
thermogenesis (heat production) in mitochondria that are upcoupled
72
. Second, the excess 
calories can be burned by increased expenditure such as exercise
72
. Third, the unused 
calories can be converted to fat and stored in adipose tissue
72
.  
Under normal conditions adipose tissue will clear the TAGs in circulation following 
intake of dietary lipids
79,80
. By this process, adipose tissue prevents free fatty acids from 
being released into circulation
79,80
. Obese subjects with excess visceral fat experience a 
failure of adipose tissue to store the amount of excess free fatty acids and TAG
79,80
. The 




2.2.3 Obesity and Adipose Tissue Inflammation  
Elevated levels of free fatty acids as that observed in obesity have the ability to 
activate the innate immune response
81
. Through interaction with Toll-like receptor-4 
(TLR-4) free fatty acids initiate a battery of adipose tissue inflammatory pathways
79,82
. 
Pathways contributing to the adipose tissue inflammatory cascades include NLRP3 
inflammasome-mediated
83-85








. The increased systemic inflammation observed in obesity is largely 
a result of these activated inflammatory pathways
64
.  As a consequence of inflammatory 
cascades in obesity adipose tissue becomes an active endocrine organ
87
. The term 
“metaflammation”or metabolic inflammation is the result of obesity induced adipose 
tissue endocrine function
80,81
. Chronic excessive calorie intake leads to increased lipid 
filling in white adipocytes resulting in cytokine release and apoptosis
73
. Upon adipocyte 
apoptosis there is a release of free fatty acids by breakdown of stored TAG
73
. Monocytes 
are recruited to adipose tissue due to increases in cytokine and chemokine secretion
73
. 
Macrophages undergo a transformation from the M2 phenotype to the inflammatory M1 
phenotype associated with obesity
73
. These activated macrophages ingest adipocyte 
debris by phagocytosis
73
.  Activated adipose tissue M1 macrophages contribute to 
increased levels of inflammatory cytokines such as TNFα
73





. This inflammatory adipose tissue increases inflammatory 
and oxidative stress systemically as well as locally
73
. It is this inflammation that links 
obesity to insulin resistance and subsequent development of diabetes mellitus, 
cardiovascular disease, metabolic disorders, cancer, and airway disease
73
. Endoplasmic 
reticulum (ER) stress along with protein kinases such as c-Jun N terminal kinase (JNK) 
and IκB kinase IKK that initiate release of inflammatory cytokines from adipose tissue 
are induced by excess nutrients such as free fatty acids (FFA)
79
. Over production of IL-1β 
due to increased number of macrophages in obese adipose tissue leads to increased 
airway hyperresponsiveness and proliferation as well as activation of IL-17 producing 




Obesity increases M1 activated macrophages as well CD4+ Th1 cells mast cells and 
CD8+ effector cells
85
. Decreased in the obese state are M2 macrophages Th2 cells, T reg 
cells, and eosinophils.  
2.3 Adipokines 
2.3.1 Cytokines in Adipose Tissue  
Adipose tissue secretes adipocytokines or adipokines as well as other 
inflammatory mediators that significantly contribute to the systemic inflammation in 
obesity
87,91
. Once thought as just a tissue responsible for storing energy reserves adipose 
tissue has emerged as an active endocrine organ
73
. Adipokines or peptide hormones 
produced by adipocytes have the ability to work locally (autocrine and paracrine) or 
systemically (endocrine)
72
. These adipokines relay information to the brain and to other 
tissues in the body about the content of energy reserves in adipocytes
72
. The first theory 
postulated about adipose tissue involvement as an endocrine organ was termed the 
“adiposity negative-feedback” model
72
. This theory postulated that when the body weight 
exceeded a particular value (set point) a protective mechanism would take into effect that 
would increase energy expenditure and inhibit eating behavior to prevent further weight 
gain
72
. The model predicted that the part of the brain responsible for metabolic and motor 
activity was influenced by a signal originated in adipose tissue
72
. Evidence of an 
adipocyte derived signaling factor that matched the postulated model came with the early 
nineties discovery of the adipokine leptin
72
. Under normal conditions, leptin modulates 
eating behavior and fuel metabolism to maintain body mass and adequate fuel reserves
72
. 
However, any alteration in adipokine production such as that observed in obesity leads to 
dysregulation and subsequent chronic metabolic related diseases
72
. Adipokine over or 
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under production is the principal link of obesity to the low grade systemic inflammation 
now considered characteristic of the disease
72
. The increased inflammatory cytokines 
have been proposed to link obesity to co-morbidities such as cancer, diabetes mellitus, 
hypertension, cardiovascular disease, and asthma
73
. 
2.3.2 Leptin  
Leptin the first identified adipokine, comes form the Greek word for “thin” and 
curbs appetite by influencing the hypothalamus
72,92
. Discovered to be the product of the 
OB (obese) gene, leptin studies were first conducted in mutant mice
72,92
. It was reported 
that mice genetically altered to not produce leptin had an insatiable appetite; high cortisol 
levels, did not reproduce, and grew abnormally to become severely obese
93
. However, 
when exogenous leptin was injected into these mice they were shown to increase 
locomotor and thermogeneic activity, lose weight, and eat less
93
. Leptin interacts with the 
leptin receptor, which is expressed primarily in the arcuate nucleus of the hypothalamus, 
the part of the brain that controls feeding behavior
93
. In morbidly obese individuals, 
leptin is found in concentrations four to six times higher than levels in a normal weight 
person
93
. It has been suggested that due to the positive association of increased adiposity 
and leptin levels, leptin may be an important link between inflammatory effects and 
obesity
92,93
. Leptin has been associated with obesity co-morbidities including asthma
94
. 
Increased leptin levels promote activation of alveolar macrophages in the lungs
95
. 
2.3.3 Adiponectin  
  Adiponectin was first identified and described over 20 years ago by the Scherer et 
al 
96




. It was once thought to be the most abundant transcript 




.  Known 
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to have anti-inflammatory properties, adiponectin has been reported to have an inverse 
relationship with BMI
103
. Three forms of adiponectin, have been identified in plasma of 
humans and mice. Characterized by corresponding molecular weight low molecular 
weight adiponectin (LMW) weighs 67kD, middle molecular weight (MMW) 136kD, and 
high molecular weight 300kD, which is thought to be the most physiologically active of 
the three
104-107
. Produced mainly by visceral fat, Adiponectin is an adipokine insulin-
sensitizing hormone and is generally associated with ant-inflammatory effects
108
. 
Adiponectin is a unique adipokine in that levels decrease with excess adiposity.  It has 
been shown to induce anti-inflammatory cytokines IL-10 and the IL-1 receptor 
antagonist, to suppress NFκB signaling, expression of adhesion molecules, and 
proliferation of vascular smooth muscle cells
109-111
. Reduced adiponectin has been 
implicated in the pathogenesis of a variety of metabolic diseases such as insulin 
resistance and coronary vascular disease
112,113
. Therefore, a role in the pathogenesis of 
asthma is also very likely since human ASM cells express adiponectin receptors (Adipo 
R1 and R2)
114
. Although an epidemiological association between adiponectin and asthma 
has not yet been demonstrated
61
 reports from recent studies suggest a relationship 
between asthma and adiponectin levels
115
. Shore et al found that exogenous adiponectin 
administration was sufficient to induce a 60% increase in serum adiponectin in a mouse 
model of asthma resulting in significant suppression of the OVA-induced inflammatory 
response and bronchial hyperreactivity
116
. In addition, adiponectin deficient mice exhibit 
a pulmonary vascular phenotype characterized by upregulation of E-selectin and 
increased perivascular inflammation
117
. This phenotype was even more apparent in older 
mice suggesting that prolonged adiponectin deficiency as seen in obesity may lead to a 
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progressive inflammatory pulmonary vascular phenotype
117
. Similarly, adiponectin 
knockout mice (APN
-/-
) exhibit severe pulmonary arterial muscularization and 
exaggerated allergic airway inflammation in response to chronic OVA challenge 
compared to wild-type mice
118
. Further, low serum levels of adiponectin are associated 
with increased asthma risk
119
 and deficient levels are observed during asthma 




 models. High serum levels of adiponectin 
protect against asthma
63




2.3.4 Tumor necrosis factor alpha (TNFα)  
One of the first reports linking the metabolic abnormalities of obesity with 
inflammation was a rodent study where diet induced obesity increased levels of the 
cytokine TNFα
120
.  Secreted from macrophages, mast cells, eosinophils, neutrophils, 
smooth muscle cells, fibroblasts and epithelial cells in response to potential stimuli, 
TNFα can augment mast cells activation via a positive autocrine feedback loop and 
thereby induce its own production and release
48
. Notably, adipose tissue is also a 
significant source of TNFα, with increased levels found with increased adiposity
73
. The 
effects of TNFα are multiplex; it increases the transepithelial migration of neutrophils by 
increasing the expression of adhesion molecule such as ICAM-1 and VCAM-1 which 
promotes chemotaxis of eosinophils and monocytes, it has a role in T-cell activation, has 
powerful growth-promoting effects on myofibroblast proliferation and induces 
hyperreactivity
48,49,121,122
. Accordingly, TNFα blocking strategies were demonstrated to 
suppress airway inflammation in a murine model of asthma
123
 Further, patients with 




. Some studies have suggested a relationship between the severity of asthma 
and levels of TNFα
20
.  The difficulty in controlling and treating the phenotype of obese 
asthmatics could be the result of elevated TNFα levels
48,49
. 
2.4 Asthma and Obesity Connection 
2.4.1 Oxidative Stress 
In addition to inflammatory stress, obesity and asthma are also associated with an 
increase in oxidative stress biomarkers in mice and humans
40,125,126
. This increase is most 
likely due to the underlying airway inflammation with recruitment and activation of 
inflammatory cells producing reactive oxygen species (ROS)
127
. Oxidant stress also 
promotes epithelial damage and inflammation as well as airway smooth muscle 
contraction and induction of airway hyperresponsiveness 
128-130
. Oxidative stress alters 
the balance of inflammatory and anti-inflammatory cytokines secreted by adipose tissue; 
increased ROS suppresses adipose tissue expression of adiponectin and increases 
expression of inflammatory factors, including TNFα
44
, while suppression of ROS exerts 
the opposite effect
131
. Thus the combination of both conditions may have synergistic 
effects and may contribute to the severity of asthma observed in obese subject
2
. 
2.4.2 Calcitriol and Adipocyte Derived Oxidative Stress 
Adipose tissue is a significant contributor to systemic oxidative stress
125
. Fat 
accumulation stimulates NADPH oxidase 4 (Nox 4), a key factor in cellular ROS 
production
44
 resulting in elevated ROS with excess adiposity. Adipocyte ROS production 
is modulated by mitochondrial uncoupling status and cytosolic Ca
2+ 
signaling, both of 
which are regulated by calcitriol in murine and human adipocytes 
132-134
. Calcitriol 
suppresses the expression of adipocyte uncoupling protein 2 (UCP2), resulting in greater 
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mitochondrial membrane potential, and stimulates cytosolic Ca
2+ 
signaling, both of which 
lead to increased ROS production 
131,133,134
. It was recently shown that physiological 
concentrations of calcitriol (100pM-10nM) dose-dependently stimulate ROS production 
in both murine and human adipocytes via both Nox 4- dependent and Nox 4-independent 
mechanisms and concomitantly stimulate expression and secretion of inflammatory 
cytokines, including TNFα, while inhibiting adiponectin expression and secretion 
131,133,134
. Further, calcitriol exerts comparable effects in macrophages and stimulates 
macrophage-adipocyte cross talk and inflammatory response in co-culture
131
.   
2.5. Asthma and Obesity 
2.5.1 Common Pathologies 
  In industrialized countries obesity and asthma are worrisome and growing public 
health issues
68
. The overweight and obese population are not only more likely to develop 
asthma but also seem to have a harder to control phenotype of asthmatic disease that is 
often refractory to standard treatments
60,135
. Obesity is now emerging as a widely 
accepted promoting factor for asthma
136
. Although, the link between the disorders is 
becoming undeniable, the mechanistic pathology of this association remains elusive
137
. 
Several factors may explain the link between obesity and asthma. The mechanical load of 
excess adiposity may lead to an overall reduced pulmonary function which includes a 
reduction in the functional residual capacity and a lower tidal volume resulting in 
shortened airway smooth muscle, decreased tension, and greater muscle stiffness
137, 138
, 
possibly leading to bronchial hyperresponsiveness. However, this is unlikely to be a 
primary mechanism, as increased risk is found with even modest increases in body mass 
index. Obesity and asthma share common inflammatory and oxidative stress markers that 
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suggests the relationship may be immunological
2
. One potential connection between the 
two disorders lies in the low-grade systemic inflammation that characterizes obesity
80
. 
The risk for asthma increases with increasing BMI, while weight loss can improve the 
course of the illness. Camargo et al. found a positive association between asthma 
incidence and body mass index in the Nurses’ Health Study II
47
. Over 85,000 women 
were followed for 4 years in the Nurses’s Health Study II, including 1,500 who had 
asthma
47
. The study reported that as the definition of asthma became more specific, the 
positive relationship between asthma incidence and body mass index became stronger
47
. 
Data from the Coronary Artery Risk Development in Young Adults study, however, 
found only women showed a significant association between obesity and asthma
139
. 
Although the study followed participants over 10 years, only 310 of the 4,547 people had 
asthma
139
. Similarly, Canada’s Nation Population Health survey also found the self-
reported asthma and body mass index to be associated only in women
56
. A pitfall of this 
study, however, is that asthma was self-reported and not clearly defined
56
. Also, the 
sample size of 127 women and 49 men participants with asthma was very small 
compared to the over 9,000 total in the study
56
.  A study conducted with Finnish 
participants found an increased risk in asthma in adults over 30 years of age if they were 
obese in their teen years
140
. Furthermore, the same study found that participants that were 
obese in adulthood (31 years of age) as well as in their teen years (14 years of age) were 
twice as likely to suffer from adult asthma compared to those that were not obese at either 
point
140
. A study conducted by Guerra et al found an increased risk of future asthma 




. However, the 
study also found this association less strong in men compared to women
141
. A recent 
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follow-up in Finnish twins found participants with a normal body mass to have 
substantially lower risk of asthma development than obese participants
142
. A moderate 
increase in risk for asthma development in obese adults was also found in the National 
Health and Nutrition Examination Survey (NHANES) I Epidemiologic Follow-up Study 
143
. Notable in all these prospective studies, obesity preceded asthma development
60
.  
Children and adolescents also exhibit an association between obesity and asthma in 
prospective studies
144
. The Children’s Health Study found that obese and overweight 
boys had a significant increased risk of asthma development, but the association was not 
found in girls
145
. However, a study in US cities found the risk of asthma was positively 




Researchers have yet to agree upon a unified definition of the disease due to the 
complexity of the group of airway conditions classified under the asthma umbrella
55
. The 
absence of a proper definition of asthma has left different definitions used in different 
research projects
55
. Criteria for individual study definitions may be based on pulmonary 
function tests, questionnaire data, or clinical symptoms depending on the researcher
55
. In 
recent years, new asthmatic phenotypes have been reported in up to 50% of adult 
asthmatics that do not have eosinophilic inflammation, are not IgE dependent, and are not 
atopic
147
. Though immunological mechanisms may vary between the two, both non-
atopic and atopic asthma are reported to have similar clinical symptoms
148
. New 
phenotypes such as the unique obese asthmatic phenotype have emerged based upon 




Initial hypotheses about obesity-associated asthma did not regard airway 
inflammation as a physiological link between the two disorders
137,149
. However, recent 
studies have reported that obese asthmatics have a neutrophil dominant type of airway 
inflammation
70
. The emerging evidence suggesting neutrophilic-based airway 
inflammation in obese asthmatics is particularly pronounced in women
71,150
.  One such 
study, found that increased neutrophilic airway inflammation and obesity are 
associated
151
. Obesity-associated phenotype is regarded as one of the most difficult to 
control and treatment refractory phenotypes of asthma
151
. Symptoms that are left 
uncontrolled result in more frequent acute exacerbations (asthma attacks) and a higher 
likelihood of lung function loss and even death
151
. It is possible that the suggested 




 2.5.2 Weight Loss in Obese Asthmatics  
In support of the obesity and asthma connection, several studies have shown 
weight loss to improve the course of asthmatic illness
154-158
.  Bariatric surgery resulted in 
significant improvements of clinical symptoms in morbidly obese asthmatics
154-158
. 
Furthermore, studies by the Macgregor et al
154
 and Dhabuwala et al
157
 reported that 
airway conditions were resolved in up to 50% of patients with asthma after receiving 
weight loss surgery. Quality of life in terms of asthma severity score, hospitalization, 
number of attacks, and medication use significantly improved in up to 90% of obese 
asthmatics after bariatric surgery
60
. A study conducted in Swedish obese asthmatics 
found patients surgically treated had substantial reductions in medication costs compared 
to those treated with conventional methods
159
. Studies involving obese asthmatics and 
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bariatric surgery are have shown promising results, however, study design, definitions of 
asthma, objective measures, and post surgery diet variations across trials are worth 
noting
60
. The absence of control groups in the obese asthmatic bariatric studies, lack of 
definitive measures of medication use, as well as absent bronchial reactivity and 
pulmonary function data have sparked some debate about interpreting results
60
. 
Additionally, some would argue that the improvement of the composition of diet as well 
as decreased energy intake after surgery might at least in part be responsible for 
respiratory health improvements opposed to weight loss alone
154,160
. 
2.5.3 Diet Interventions in Obese Asthmatics 
The effects of weight loss on asthmatic symptoms have been examined in studies 
using non-surgical interventions in obese asthmatics such as diet modification
161
. The 
Stenius-Aarniala et al used a very-low-calorie diet implemented for an eight week 
duration in a randomized clinical trial to induce weight loss in obese asthmatics and 
observed favorable changes in forced expiratory volume (FEV1), health status, dyspnea, 
forced vital capacity (FVC), number of acute exacerbations (asthma attacks), as well as 
use of rescue mediation were observed in those assigned to the very-low calorie diet in 
measurements taken at the end of the 8 week period and a year later
161
.  On average those 
in the experimental diet group ended the study with a 14.5% reduction in their body 
weight, possibly explaining disease improvement
161
.  A similar study reported a 14% 
body weight loss in obese asthmatic fed very-low-calorie diet for 8 weeks
162
. Participants 
in the experimental diet group were observed to have improvements in day-to-day 
variation, FEV1, peak expiratory flow, ratio of forced midexpiratory flow rate to FVC, 




. Albeit uncontrolled, another study utilized diet 
modification in obese asthmatics by 6 or 12-week study design based on the degree of 
obesity where patients were place on a 900kcal/day diet
163
. The average participant lost 
17.4% of their pretreatment weight
163
. This study also introduced an exercise component 
that may explain the increase in body mass loss compared to studies using only diet 
interventions
163
. Positive changes were observed by the improvement of total lung 
capacity, FVC, and FEV1, however, bronchial reactivity was unchanged
163
.  
2.6 Dairy Food Components, Asthma, and Adipose Tissue Inflammation 
2.6.1 Dairy and Asthma 
Despite controversial claims suggesting that milk or dairy consumption may 
trigger asthma attacks or promote mucus production, supporting scientific evidence for 
these claims is scant and could be found only for subgroups of patients and is confounded 
by claims regarding the source of the milk and underlying medical conditions 
164
. In 
contrast, epidemiological studies suggest a protective role for dairy products, calcium and 
Vitamin D intake in the development of allergic disease and asthma 
165-168
. A study 
reported by Wijga et al.
165
 found that daily full cream milk and butter consumption at age 
2 significantly lowered the subsequent incidence of asthma and wheezing at age 3 (3.4% 
vs. 5.6% and 13.7% vs. 18.4%, respectively). Waser et al 
168
recently found an inverse 
association of farm milk consumption with asthma in schoolchildren from rural and 
suburban populations across Europe, and Hijazi et al.
166
 reported low intake of milk as a 
significant risk factor for wheezing illness. Moreover, a prospective study
167
 examining 
the association between maternal consumption of dairy products, calcium and vitamin D 
during pregnancy and the later risk of wheeze and eczema in the infants found a 
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decreased risk of infantile wheeze with higher maternal intake of total dairy products, 
milk, cheese, calcium and Vitamin D during pregnancy. Multiple components in dairy 
may be responsible for these protective effects. One study found that cis-9, trans-11-
conjugated linoleic acid, a naturally occurring fatty acid in milk fat, significantly 
inhibited airway inflammation, airway hyperresponsiveness and mucous plugging in a 
murine model of asthma, which may explain the protective effects of butter and full 
cream milk
169
. In another study, Lee et. al 
170
 administered kefir powder through 
intragastric feeding to a mouse model of asthma and found significant anti-inflammatory 
and anti-allergic effects after treatment. Although the authors suggested that these effects 
might be caused by the high microbial content of kefir, it is plausible that other 
components such as calcium and leucine may also play a significant role; which supports 
the premise presently in review. 
2.6.2 Dietary Calcium Suppression of Calcitriol 
The ability of dietary calcium-induced suppression of calcitriol (elevated in 
calcium deficiency; ~70% of the obese) to attenuate oxidative and inflammatory stress 
was shown by Zemel et al where a significant, substantial suppression of both adipose 
tissue and systemic oxidative and inflammatory stress in a mouse model was reported 
132,171
. The findings prompted the dietary interventions to be extended to clinical trials in 
overweight and obese subjects where it was found that suppressing circulating calcitriol 
with calcium-rich diet suppressed systemic oxidative stress by ~20%, reduced circulating 
TNFα and increased adiponectin by 20% (p<0.002) in a randomized, blinded cross-over 
trial design
171,172
. Although calcitriol has been recently reported to inhibit ASM 
proliferative response to PDGF
173
, this effect occurs at concentrations that are 50-500 
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fold higher than physiological plasma concentrations (IC50=520nM). These 
concentrations may be achieved in some tissues, such as the prostate, in vitamin D replete 
individuals and are relevant to autocrine signaling, but are not relevant to the endocrine 
signaling role of calcitriol proposed in Zemel et. al studies among others. 
The two broad categories of vital calcium function are structural and signal 
transduction
73
. Calcium is considered to be the “universal second messenger”
73
. As 
secondary messenger calcium is responsible for nerve conduction/neuromuscular 
transmission, muscle contraction, membrane transport, hormone secretion, blood 
coagulation, cell growth, cell division, cell adhesion
73
. Less than one percent of skeletal 
calcium is available for exchange on short notice and this fraction is found in the 
extracellular bone fluid surrounded by “osteocytic membrane system”
73
. This is also the 
system involved with bone remodeling regulating bone resorption and deposition as well 
as osteoclast activation
73
. In the plasma, calcium exists as the ionized form (Ca
2+
) 
representing ~50% of total plasma calcium
73
. The second most prominent form of 
calcium is protein bound composing about 45% of circulating calcium
73
. Approximately 
five percent of plasma calcium is complexed in the form of Ca-citrate, Ca-lactate, Ca-
bicarbonate, or Ca-phosphate
73
. Ionized calcium and complexed calcium are both 
considered as ultrafilterable
73
. After kidney filtration of calcium, 98-99% is reabsorbed, a 
process that is regulated in part by the parathyroid hormone
73
. Calcium enters cells via 
parathyroid activated calcium channels and is transported across the cell by calbindins 




 ATPase regulated by parathyroid hormone 
and calcitriol along with the 3Na+/Ca
2+
 exchanger transport are responsible for calcium 
extrusion
72
. In the gastrointestinal tract calcium is absorbed by active transport at the 
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brush border by Ca-dependent-ATPase, although some transport is passive
72
. The 
transport is regulated by calcitriol, which is elevated when calcium intake is low and 
decreased once calcium intake is adequately restored
72
. Absorption is decreased with 
complexation such as binding to oxalic acid (from dietary sources) resulting in insoluble 
salt crystals
73
. Additionally, high-fiber foods and whole-grain foods high in phytic acid 
decrease calcium absorption in a similar way
73
. Further, long term use of medications, 
such as corticosteroids may also alter calcium absorption
73
. An alkai intestinal 
environment decreases calcium absorption due to the necessity of acidic conditions for 
calcium carbonate to dissolve
73
. Therefore, high protein diets that increase intestinal 
acidity in turn facilitate calcium absorption
73
. Once calcium carbonate is dissolved in the 
intestine it can then be absorbed into the blood
73
. A normal blood calcium level is ~ 2.2-
2.6 mmol/L or 9-10.5 mg/dL total calcium and if levels fall below this range the 





uptake and stimulates 1α hydroxylase activity in the kidneys to 
convert 25OH vitamin D to 1, 25-diOH vitamin D (calcitriol)
73
. Calcitriol then stimulates 
Ca
2+
 uptake in the intestines as well as stimulates Ca
2+ 
release from the bone to restore 
calcium levels to a normal range
73
. If calcium levels increase above the normal range, the 
thyroid gland is stimulated to release calcitonin, which stimulates Ca
2+
 deposition in the 




The label of “vitamin D” is used to describe both D3 (cholecalciferol) and D2 
(ergocalciferol) forms of the micronutrient 
174,175
. Most terrestrial animals and living 
plants can produce one or both major forms of vitamin D 
174
. Typically, vitamin D2 is 
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major form synthesized in plants due to the interaction of the provitamin D2 ergosterol 
and ultraviolet B light 
176
. Humans can only synthesize D3 but can metabolize both D2 
and D3
174
. The more active form of vitamin D is vitamin D3 that is found naturally in 
very few foods 
177
. Natural sources of vitamin D3 are mainly fatty fish such as mackerel, 
sardines, and salmon
177,178
. The chief dietary sources of D3, outside of these natural 
sources, are fortified foods such as select cereals and milk
178
. The average person 
typically obtains only ten percent of their vitamin D from dietary sources
174
. For most 
people, the main supply of vitamin D3 is produced from the interaction of a chemical in 




. The chemical 7-dehydrocholesterol, or 
provitamin D3 (found in the dermal layers of the skin), forms cholecalciferol after being 




. Cholecalciferol is then converted to 25- 
hydroxycholecalciferol (25OHD, or calcidiol) by enzymatic action in the liver
175,179,180
. 
Circulating vitamin D, whether obtained from synthesis in UV-exposed skin or from the 
diet, is stored in adipose tissue or rapidly converted to 25OHD
180
. After this reaction, 
the mitochondrial enzyme 1, α-hydroxylase (CYP27B1) is needed to convert 25OHD to 
the primary active form of calcitriol (1α, 25-dihydroxycholecalciferol) 
175,179,180
. The 
CYP27B1 enzyme is expressed in many tissues throughout the body including the 
placenta and kidneys
175,179,180
. The now active calcitriol plays a critical role in calcium 
homeostasis in the body 
174,180
.  
Vitamin D is a secosteroid hormone
72
. As a steroid hormone vitamin D acts via a 
receptor superfamily
72
. Once vitamin D binds to a receptor, it exposes a DNA binding 
region and subsequently increases transcription of some mRNAs and decreases 
transcription of others
72
. The vitamin D receptor is present in many tissues and helps to 
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carry out multiple functions
72
. A steroid hormone functions by binding to its counterpart 
where the now complexed steroid-receptor complex will translocate to the nucleus
72
. In 
the nucleus, the complex will bind to a DNA regulatory site and regulate transcription of 
multiple mRNAs and subsequent protein translation in the cytoplasm
72
. Vitamin D 
increases calcium and phosphorus absorption from the gastrointestinal tract (GI), 
increases calcium binding proteins such as calmodulin, increases calcium transport, 
increases renal calcium reabsorption, and increase mature osteoclasts to mobilize calcium 
and phosphorus from bone
72
. Free calcium in the cell [Ca
2+
] is around 100nM while free 
Ca
2+
 in the blood is around 1.2 mM
73
. Calcium release from the bone is also increased 
when levels of calcitriol are increased
73
. When calcium levels are adequate in the body 
calcitonin is released, which then inhibits the release of calcium from the bone
73
.  
2.6.3 Leucine and Oxidative Stress  
  Dairy protein is rich in branched chain amino acids, including leucine. Recent 
data supports a role for leucine in attenuating oxidative and inflammatory stress
181,182
. We 
have found leucine (0.5 mM, comparable to levels achieved following a leucine rich 
meal) to stimulate mitochondrial biogenesis in both adipocytes and muscle cells, with an 
associated increase in oxygen consumption and fatty acid oxidation in both cell types
182
. 
This increase in energy utilization reduces the oxidative and inflammatory stress that 
otherwise result from nutrients and overload and obesity. The positive effects of leucine 
on mitochondrial metabolism have been shown to be mediated, at least in part, by sirtuin 
1 (Sirt1), as leucine stimulates Sirt1 activity, while knockdown of Sirt1 inhibits leucine-
stimulation of mitochondrial biogenesis and metabolism
182,183
. To test the systemic 
effects of leucine and calcium (in the form of dairy foods) on Sirt1, an ex vivo approach 
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was utilized to examine the integrated effects of dairy diets in adipocytes and skeletal 
muscles
183
. Serum from 20 overweight and obese subjects fed low or high dairy diets for 
28 days were used to reflect the integrated systemic response to the diets and was then 
added to culture medium (similar to a conditioned medium approach) to treat cultured 
adipocytes and muscle cells for 48 hours
183
. Serum from participants fed a high, but not 
low dairy diet, resulted in a 40% increase in Sirt1 expression vs. baseline serum in both 
tissues (p<0.01) and a 30% increase in Sirt1 activity in adipocytes (p<0.05)
183
. This was 
associated with increased expression of adipocyte mitochondrial NADH dehydrogenase 
and UCP2 (p<0.04) and muscle UCP3, NRF1, and COX7 (p<0.03)
183
. Sirt1 activation of 
PGC1-α not only drives an increase in mitochondrial energy metabolism, but also induces 
antioxidant enzymes such as manganese superoxide dismutase
184
 and inhibits NF-κB 
activity
182,184
, thereby attenuating oxidative and inflammatory stress, respectively. 
Accordingly, leucine markedly inhibits the expression and secretion of inflammatory 
cytokines while increasing adiponectin expression and secretion ~two-fold in cultured 
adipocytes
181
. A published microarray study demonstrated that suppression of calcitriol 
by calcium feeding and increased leucine intake each up-regulated Sirt1-dependent 
signaling pathways for fat oxidation and attenuation of inflammatory response (including 
NFκ-B signaling) and attenuated pathways such as MAPK and JAK-STAT signaling 
associated with proliferations of cell cycle regulation
185
.  
2.7 Leucine Molecular Mode of Action 
2.7.1 Sirtuins 
Sirtuins are a group of nutrient sensing proteins characterized as class III 
deacylases that need NAD
+




characterized as a repressor of gene transcription at selected loci by acting as a chromatin 
silencing component the first identified sirtuin protein silent information regulator 2 
(SIR2) was discovered in yeast
188
. Sirtuins are energy sensing proteins that are diet-
sensitive, anti-aging, and are conserved
187
. The anti-aging properties of sirtuins defined in 
yeast, fruit flies, C.elegans and were also found to be conserved in mammals
189,190
. Three 
sirtuin proteins (Sirt1, Sirt6, and Sirt7) have been found to localize in the nucleus where 
they regulate gene transcription in response to energy changes
187
. Only recently was Sirt2 
also found in the nucleus where it is distinct in function by modulating cell cycle 
control
191-193
. The other three sirtuins Sirt3, Sirt4 and Sirt5 are found in the mitochondria 
making up the total of seven mammalian sirtuins currently identified
187
. Cellular 
responses can be coordinated throughout the organism in times of caloric restriction due 
to the specific cellular compartments in which sirtuins are located
194
. Sirtuins found in the 
nucleus such as Sirt1, Sirt6, and Sirt7 influence gene expression by the epigenetic process 
of histone deacetylation
194
. Additionally, it has been found that Sirt1 influences the 
activities of enzymes and specific transcription factors by deacetylation
187
. Mitochondrial 
sirtuins Sirt3, Sirt4, and Sirt5 modulate oxidative stress in their organelle of residence 
and regulate activities of metabolic enzymes
195
. In response to caloric restriction (CR) 
mitochondrial sirtuins switch cellular processes to support mitochondrial oxidative 
metabolism as well as turn on genes for stress tolerance
187
. In humans, Sirt1 is activated 
in response to caloric restriction
196
 by sensing increased NAD
+ 
levels, accordingly, 
expression is reduced in obesity
197,198
.  Sirt1 functions in key metabolic tissues such as 
white adipose tissue (WAT), liver, heart, and skeletal muscle
187
. Gluconeogenesis is 
supported by Sirt1 in the liver via peroxisome proliferator-activated receptor (PPAR) γ 
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co-activator 1α (PGC-1α) and forkhead box O1 (FOXO1)
199
. In prolonged fasting, Sirt1 
facilitates the degradation of CREB-regulated transcription co-activator 2 (CRTC2)
200
.  
Fatty acid oxidation is promoted in the liver by SIRT1 in response to fasting by the 
activation of peroxisome proliferator-activated receptor α (PPARα)
201
. Fatty acid 
synthesis in the liver is inhibited by SIRT1 targeting of sterol regulatory element binding 
protein 1c (SREBP1c) for degradation
202
. Systemic cholesterol homeostasis is controlled 
by SIRT1 via positive regulation of the liver X receptor (LXR)
203
.  In skeletal muscle 
SIRT1 acts in a similar manner with the overall effects of reducing glycolysis and 
increasing fatty acid utilization
204
.  In this tissue, AMP-activated protein kinase and 
SIRT1 share positive loop of regulation
187
. AMPK up regulates the gene encoding the 
NAD
+ 
synthetic enzyme nicotinamide phosphoribosyltransferase (NAMPT), thereby 
increasing amounts of NAD
+ 
necessary for SIRT1 function
205,206
. In turn, SIRT1 works 
reciprocally by deacetylating liver kinase B1 (LKB1) resulting in the phosphorylation 
and activation of AMPK
207
. Lipid utilization in muscle and liver is driven by SIRT1 
activation of PPARγ in white adipose tissue (WAT) allowing the mobilization of fat to 
peripheral tissues
208
. Additionally, enhanced energy expenditure is increased by SIRT1 
by driving white fat browning
209
. SIRT1 induced white fat browning is initiated through 
PPARγ deacetylation facilitating the binding of PR domain containing 16 (Prdm16)
209
. 
The anti-inflammatory adipokine adiponectin up regulates SIRT1 protein
210
 whereas 
caspase I degrades SIRT1 after post high fat diet activation
211
. Sirtuins are also beneficial 
to the vascular system by activating endothelial nitric oxide synthase (eNOS) resulting in 
increased ischemic tolerance
212
. Also, SIRT1 induced PPARα activation has shown to 




2.7.2 Peroxisome Proliferator-Activated Receptors (PPARs) 
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear 
receptors that regulate gene transcription
72
. Currently, there have been three identified 
PPAR proteins PPAR-δ, PPAR-α, and PPAR-γ
214
. Ligand activated PPAR proteins 
respond to dietary lipid changes by altering carbohydrate and fat metabolism genes
72
. 
Fatty acid derivatives and fatty acids are common ligands for PPAR family members that 
work in conjunction with the retinoid X receptor to form heterodimers
72
. These 
heterodimers allow for the binding of the complex to regulatory regions of DNA and 
change the rate of transcription of associated genes as a result
72
. Genes necessary for the 
differentiation of fibroblasts into adipocytes, lipid storage in adipocytes, and synthesis are 
regulated by the PPARγ nuclear receptor
72
. Adipose tissue (both brown and white) and 
liver are the two types of tissues where PPARγ is predominantly expressed
72
. The type 2 
diabetes medication thiazolidinedione drugs activate PPARγ
72
. The genes that turn on β-
oxidation of fatty acids in the liver are controlled by PPARα
72
. Present in the liver, 
skeletal muscle, brown adipose tissue, heart, and kidney PPARα is also needed for ketone 
body formation during times of fasting
72
. The most important PPAR in terms of potential 
drug development to treat obesity is the PPARδ, which acts in the muscle and the liver
72
. 
Dietary lipids stimulate PPARδ to induce transcription of genes necessary for β-oxidation 
as well as those that act to uncouple mitochondria to increase energy dissipation
72
. 
Animal studies using high-fat diets have shown that transgenic mice with an always 
active PPARδ to be immune to excess fat accumulation
72
. PPARδ activation results in 





2.7.3 AMP-activated protein kinase (AMPK) 
Phosphorylation by AMP-activated protein kinase (AMPK) of target proteins 
results in increased substrate oxidation for energy production
73
. Fatty acid synthesis is 
inhibited and fatty acid oxidation is activated as downstream consequences of AMPK 
phosphorylation
73
. Primarily, these AMPK induced responses occur in the muscle and 
liver and become necessary in times of nutritional deprivation
73
. 
2.7.4 Effects on Obesity Related Oxidative Stress 
We have previously reported that calcitriol increases inflammatory and oxidative 
stress in murine adipocytes and muscle cells in an in vivo model while dietary calcium 
suppressed calcitriol and alleviated the adverse response
171,215,216
. Investigations into high 
calcium foods such as dairy revealed a significantly superior effect compared to calcium 
alone
217
. Retrospective analysis of serum samples from previous clinical trials also 
suggested a protective response from dairy food consumption in obese humans
217
. 
Observations from these studies were used to design a randomized double blind study 
where dairy-based smoothies significantly increased anti-inflammatory adiponectin while 
decreasing IL-6, monocyte chemoattractant protein 1, C-reactive protein, and TNFα 
inflammatory markers and 8-isoprostane F2α and malondialdehyde oxidative markers in 
otherwise healthy overweight and obese subjects
172
.  
2.8 BALB/cAnNHsd Mice 
2.8.1 Overview 
Acquired from Harlan Laboratories, the albino stock was originally obtained by 
H. Bragg in 1913 and therefore called “Bragg albino” or BALB
218
. In 1923, MacDowell, 
in Cold Spring Harbor, NY, USA, inbred the mice. In 1932, at F26 to Snell, who added 
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the ‘c’ for albino
218
. The BALB/cAnNHsd line was derived from a breeding nucleus 
obtained from the National Institutes of Health, Bethesda
218
. The mouse line was 
generated to be susceptible to an allergy induced Th2 lymphocyte response
218,219
. 
Susceptibility of BALB/c mice to allergic inflammation induction led to their 
incorporation as models in asthma studies
218,219
. In a comparison study of 7 different 
strains (BALB/c, BP/2, A/J, C57Bl/6, DBA/2, CBA and AKR) of mice, it was found that 
mice with a Th2 bias, particularly BALB/c mice, were best for human phenotypical 
characteristics of asthma
219
.  The BALB/c mice strain is an established and well-studied 
model for asthma, however information on their ability to serve as an appropriate model 
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Our objectives are to determine the effects of calcium, calcitriol and leucine on 
airway smooth muscle cell and endothelial cell function and inflammation using in vitro 
approaches in human cells and in vivo studies in a mouse model of asthma. The two 
dietary components under investigation, calcium and leucine, are most abundant in dairy 
foods. Accordingly, results of this study may provide a unique opportunity to use dairy 
products as functional foods to uncouple the relationship between obesity and asthma and 
to be utilized as part of a nutritional paradigm for prevention of airway inflammatory 
disease.  
Specific Objective 1. Determine the in vitro effects of calcitriol and leucine 
treatment of murine adipocytes on human bronchial airway smooth muscle cells 
(BSMC) and lung microvascular endothelial cell (HMVEC-L) inflammation and 
function.  
To address this objective, BSMC and HMVEC-L were initially be cultured alone 
and treated with calcitriol (10 nM), L- Leucine (0.5 mM), and Nitrendipine (30 nM) for 
48 hours to assess direct effects of treatments on these cell types. Next, the indirect 
effects of above treatments on each cell-type were examined in co-culture with murine 
adipocytes to assess the effects of the altered adipose tissue cytokine expression in 
response to the treatments on BSMC and HMVEC-L function. At the end of the 
incubation cells and culture medium were collected for analysis. For both cell-types 
(BSMC and HMVEC-L), outcome measures for the inflammatory response include 
intracellular adhesion molecule (ICAM-1) and vascular cellular adhesion molecule 
(VCAM-1) as well as their cell surface markers via flow cytometry in response to the 
treatments in BSMCs and HMVEC-Ls. Further, we assessed the direct and indirect 
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(measured by using conditioned media of treated adipocytes) effects of above treatments 
on the adherence and of fluorescently labeled leukocytes to treated BSMCs and HMVEC-
Ls under physiological flow conditions using fluorescence microscopy. 
Specific Objective 2. Determine the in vivo effects of dietary calcium and leucine on 
mouse airway smooth muscle function, inflammation and airway hyper-reactivity.  
Specific objective 2 extended these findings to an in vivo system by assessing the 
effects of dietary calcium and leucine in an established mouse model of asthma. Effects 
of the diets on airway inflammation (via bronchial alveolar lavage) were analyzed. Since 
timing of the treatment relative to the onset of airway inflammation (intervention start 
before sensitization vs. after sensitization) may influence the outcome, this study was 
conducted in separate groups of animals either prior to or following sensitization to 
differentiate between preventive and therapeutic effects of the diets. 
Mouse model of asthma: Female mice were utilized, as asthma is more prevalent and 
severe in women than in men, and female mice were recently reported to exhibit more 
severe allergic airway inflammation than males in response to ovalbumin challenge or 
house dust mite exposure (1). 6 weeks old female BALB/cJ mice, purchased from The 
Jackson Laboratory (Bar Harbor, Me), were sensitized to ovalbumin to induce chronic 
allergic airway inflammation as described (2) with minor modifications. Intraperitoneal 
(i.p.) injections of 50 µg of Chicken egg albumin (ovalbumin [OVA]; Grade V, Sigma-
Aldrich, St. Louis, MO) diluted in 0.1 ml of PBS was given on day 0, 4 and 7. Starting on 
day 12, animals were challenged by aerosol challenge by nebulizer delivery of 2.5% 
OVA diluted in PBS 3 times a week for 6 weeks. Mice assigned to nonsensitized group 
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received i.p injections and aerosol challenges of PBS only. Mice were euthanized 24 
hours after last aerosol challenge. 
Treatment groups: Animals were randomly divided into 5 different treatment groups: 
• Non-sensitized control group: fed a high sucrose/high fat diet with sub-optimal 
Calcium (0.4%)  
• OVA-sensitized control group: fed a high sucrose/high fat diet with sub-optimal 
Calcium (0.4%)  
• Non-sensitized high calcium group: fed a high sucrose/high fat diet with sub-optimal 
Calcium (1.2%)  
• OVA-sensitized high calcium group: fed the same diet as control but supplemented 
with Calcium carbonate (1.2% Ca)  
• Non-sensitized Leucine group: fed the same diet as control but supplemented with 
Leucine (200% normal level)  
• OVA-sensitized Leucine group: fed the same diet as control but supplemented with 
Leucine (200% normal level)  
• Non-sensitized high calcium/Leucine group: fed the same diet as control but 
supplemented with calcium (1.2%) leucine (200% normal level)  
• OVA-sensitized high calcium/Leucine group: fed the same diet as control supplemented 
with calcium (1.2%) and leucine (200% normal level)   
Each diet group was further divided into 2 groups, one prevention group with feeding 
start before sensitization initiation, and one therapeutic group with diet start 2 days before 
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Leucine and calcitriol adipocyte treatment: 
Opposing influences on leukocyte adhesion to cell 
















The increase in inflammatory cytokines observed in obesity may link excess 
adiposity to asthmatic airway inflammation. We have previously demonstrated that 1,25 
dihydroxycholecalciferol (calcitriol) and leucine modulate adipocyte and macrophage 
inflammatory cytokine production. With the knowledge that several of these cytokines 
are involved in leukocyte adhesion and infiltration into lung endothelial and bronchial 
smooth muscle cells of the airway in asthmatic disease, we sought to determine if 
calcitriol and leucine treatment of adipocytes could alter this inflammatory process.  3T3-
L1 adipocytes were treated with vehicle, calcitriol, leucine or both for 48 hrs.  Adipocyte 
conditioned medium (CM) was collected for incubation with U937 monocytes or whole 
blood leukocyte populations for activation marker and adhesion assays or used to assess 
adhesion molecule mRNA and protein expression in human lung microvascular 
endothelial cells (HMVEC-L) and bronchial airway smooth muscle cells (BSMC). 
Compared to control, calcitriol markedly increased adhesion of human monocytes to 
BSMC by ~7 fold, from 225 ± 14 to 1557 ± 489 cells adhering/µm
2
 (p<0.001).  Leucine 
CM, however, decreased monocyte adhesion to BASM by ~40% compared to control. 
Similarly, ICAM-1 adhesion molecule mRNA was significantly lower in leucine CM 
treated HMVEC-L cells as compared to calcitriol CM samples (p<0.05). Protein 
expression of ICAM-1 increased ~40% in calcitriol CM samples compared to control CM 
(p<0.05), while leucine CM samples were decreased ~48% compared to calcitriol CM 
(p<0.01). CD11b adhesion integrin expression in whole blood leukocytes treated with 
calcitriol CM were increased ~67% compared to control CM (p<0.01).  Conversely, 
leucine CM treated leukocytes expression was reduced by ~40% compared to control CM 
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(p<0.01). Data from this study suggest opposing roles of leucine and calcitriol in obesity 
associated airway inflammation. 
4.2 Introduction 
Over the past several decades the prevalence of asthma has increased dramatically 
in urbanized nations such as the United States (1-3). Upwards of 300 million people 
suffer from asthma worldwide with over 24 million currently living in the US (1, 3). 
Accompanying asthma as a public health issue is the upsurge of global obesity incidence 
(4). With the observed parallel growth of obesity and asthma cases, an increasing body of 
evidence suggests a positive relationship between the two disorders (5). Obesity is now 
widely recognized as a key risk factor for asthma where relative risk has been shown by 
prospective studies to increase with increasing body mass index (BMI) (5, 6).  In support 
of this connection, several studies have reported increased prevalence, incidence, 
severity, and decreased control of asthma in obese individuals (7-11). There is increasing 
proof that obesity is a prompting factor for asthma, however, the mechanistic link 
between obesity and asthma remains elusive (10, 12). One hypothesis to explain the 
connection lies in the increased systemic inflammation observed with excess adiposity 
that is now a hallmark of obesity (13, 14, 15).  It has been reported that adipokines and 
cytokines derived from the adipose tissue of obese asthmatics may have a synergistic 
adverse effect on the airways (16). The defined roles of most of these intermediaries in 
the development of asthmatic disease have not been demarcated; however, the alteration 
of anti-inflammatory adiponectin (decreased in obesity) and pro-inflammatory TNFα 
(increased in obesity) adipokines has been described as potential participants in the 
pathogenesis of asthmatic disease (17-22).  
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Airway inflammation opulent in leukocytes (eosinophils, neutrophils, monocytes) is 
frequently used to characterize asthma phenotypes (23-25). The adipokine TNFα has 
been implicated in asthmatic airway inflammation in both in vitro and in vivo models (26-
28). The effects of TNFα are multiplex; it increases the transepithelial migration of 
neutrophils by increasing the expression of adhesion molecules such as intracellular 
adhesion molecule 1 (ICAM-1) and vascular adhesion molecule 1 (VCAM-1), which 
promotes chemotaxis of eosinophils and monocytes (26-28). Polymorphonuclear cell 
(PMNs) leukocytes especially eosinophils and neutrophils are critical pathogenic 
components in asthmatic disease by infiltrating the airways (29). The cytokine-induced 
increase of leukocyte activation integrins and chemotactic guidance of chemokines 
recruit PMNs from the blood to the site of inflammation in the airways (29). The 
interaction between intracellular adhesion molecules (ICAM-1) on vascular endothelial 
cells and CD11b (β2-integrin) on leukocytes secure adhesion of PMNs to endothelial cells 
(29). Contrary to the pro-inflammatory contribution of TNFα to airway inflammation the 
adipokine adiponectin appears to be beneficial in airway disease (30-32). Adiponectin has 
been shown to induce the anti-flammatory cytokines IL-10 and the IL-1 receptor 
antagonist, to suppress NF-κB signaling, and to suppress the expression of adhesion 
molecules (30-32).   
In addition to inflammatory stress, both obesity and asthma are also associated 
with an increase in oxidative stress biomarkers in mice and humans (33-35). Oxidative 
stress alters the balance of inflammatory and anti-inflammatory cytokines secreted by 
adipose tissue; increased reactive oxygen species (ROS) suppresses adipose tissue 
expression of adiponectin and increases expression of inflammatory factors, including 
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TNFα (36), while suppression of ROS exerts the opposite effect. Adipose tissue is a 
significant contributor to systemic oxidative stress. Our lab, and others has shown 
adipocyte ROS production to be modulated by mitochondrial uncoupling status and 
cytosolic Ca
2+
 signaling, both of which are regulated by calcitriol (vitamin D3) in murine 
and human adipocytes (37-39). Calcitriol (unregulated in calcium deficiency and obesity) 
suppresses expression of adipocyte uncoupling protein 2 (UCP2), resulting in greater 
mitochondrial membrane potential, and stimulates cytosolic Ca
2+ 
signaling, both of which 
lead to increased ROS production (37-40). We have recently shown that calcitriol dose-
dependently stimulates ROS production in murine and human adipocytes and 
concomitantly stimulates the expression and secretion of inflammatory cytokines, such as 
TNFα, while inhibiting adiponectin expression and secretion (37-40). Consequently, we 
evaluated the ability of dietary calcium-induced suppression of circulating calcitriol to 
attenuate oxidative and inflammatory stress and found significant suppression of both 
adipose tissue and systemic oxidative and inflammatory stress in a mouse model (37, 41). 
These studies also began to suggest a role for the branched chain amino acid leucine in 
attenuating oxidative and inflammatory stress as well (43, 44). Leucine was shown to 
stimulate mitochondrial biogenesis, oxygen consumption, and fatty acid oxidation in 
adipocytes and muscle cells (43, 44). The increased energy utilization due to leucine 
treatment in these cell types resulted in reduced oxidative and inflammatory stress that 
otherwise would result from nutrient overload and obesity (43, 44). From this previous 
data we hypothesize that the alteration in adipocyte cytokine production by leucine and 
calcitriol treatment will have opposing affects on airway inflammation. We used human 
microvascular endothelial cells of the lung (HMVEC-L) and bronchial airway smooth 
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muscle cells (BSMC) to assess adhesion molecule expression and inflammatory markers. 
Leukocytes from whole blood were used to observe CD11b integrin and activation 
marker expression and subsequent adhesion to either lung endothelial or bronchial airway 
smooth muscle cell monolayers. 
4.3 Materials and Methods 
4.3.1 Adipocyte Conditioned Medium (CM) Generation 





 dish) and grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Gibco, Grand Island, NY) containing 10% Fetal Bovine Serum (FBS) (Gibco, 
Grand Island, NY) and antibiotics (1% penicillin/streptomycin) at 37° C in 5% CO2 in 
air. Confluent preadipocytes were induced to differentiate with a standard differentiation 
medium consisting of DMEM-F10 (1:1; v/v) medium supplemented with 10% FBS, 1 
µM dexamethasone, 0.5 mM isobutylmethylxanthine, and antibiotics (1% 
penicillin/streptomycin). Preadipocytes were maintained in this differentiation medium 
for 3 days and subsequently cultured in adipocyte medium (10% FBS, DMEM, 1% 
penicillin/streptomycin). Cultures were re-fed every 2-3 days to allow 90% cells to reach 
full differentiation. Before treatments, cells were incubated in low serum medium (0.2% 
FBS, DMEM, 1% penicillin/streptomycin) overnight and then washed with fresh 
medium, re-fed with (2% FBS, DMEM, 1% penicillin/streptomycin) medium containing 
the different treatments (vehicle, 0.5 mM leucine, 10 nM calcitriol, 0.5 mM leucine and 
10 nM calcitriol combination) all obtained from Sigma (St. Louis, MO) and incubated at 
37 °C in 5% CO2 for 48 hr before conditioned media collection. Adipocyte conditioned 
medium was used immediately or stored at -80°C until needed. 
 66
4.3.2 Human Lung Microvascular Endothelial Cells (HMVEC-L) 
HMVEC-L cells were maintained following the distributor’s protocol (Lonza, 
Walkersville, MD CC-2527), in endothelial basal medium-2 (EBM-2) (Lonza, 
Walkersville, MD CC-3156) supplemented with endothelial growth medium (EGM-2) 
MV BulletKit from (Lonza, Walkersville, MD CC-3202) at 37°C and 5% CO2, until 
achieving a 70%-90% confluence. The cells were used at passages 5-9 for assays. 
4.3.3 Bronchial Airway Smooth Muscle Cells (BSMC) 





 dish) and grown in smooth muscle cell basal medium (SmBM-2) and 
corresponding bullet kit smooth muscle cell growth medium (SmGM-2) (Lonza, 
Walkersville, MD CC-3182) at 37°C and 5% CO2. BSMC were utilized for assays 
between passages 4-6.  
4.3.4 U937 Monocyte Cell Line (U937s) 
U937 monocyte cells were obtained from ATCC (Manassas, VA, USA) and 
suspensions were cultured in T-75 cm
2
 flasks with RPMI 1640 medium (Gibco, Grand 
Island, NY) supplemented with 10% FBS (Gibco, Grand Island, NY) and antibiotics (1% 
penicillin/streptomycin) at 37°C and 5% CO2. Cell density was maintained between 1 X 
10
5 
and 2 X 10
6
 viable cells/mL. Fresh medium was added every 3-4 days depending on 
the number of cells. 
4.3.5 Adipocyte-Bronchial Airway Smooth Muscle Co-Culture 
3T3-L1 mature adipocytes and BSMCs were co-cultured using transwell inserts 
with a 0.4 µm porous membrane (Corning Inc., Corning, NY) to separate adipocytes and 
BSMCs, as previous described with adipocyte-myocyte interactions (45). Each cell type 
 67
was grown independently in transwell plates and following differentiation; inserts 
containing adipocytes were transferred to bronchial smooth muscle cell plates. The cells 
are then incubated in DMEM-medium with antibiotics containing the indicated chemical 
treatments (vehicle, 0.5 mM leucine, 10 nm calcitriol, 0.5 mM leucine and 10 nM 
calcitriol combination, 30 nM nitrendipine (Sigma, St. Louis, MO), 10 nM calcitriol and 
30 nM Nitrendipine combination) and incubated at 37°C in 5% CO2 for 48 hr, after 
which cells in the lower well are harvested for further analysis and media collected for 
subsequent experiments. 
4.3.6 RNA Extraction 
The Ambion ToTALLY RNA isolation kit (Ambion, Inc., Austin, Tex., USA) 
was used to extract total RNA from cells according to the manufacturer’s instruction. The 
concentration, purity and quality of the isolated RNA were assessed by measuring the 
260/280 ratio (1.8-2.0) and 260/230 ratio (close to 2.0) by using the ND-1000 
Spectrophotometer (NanoDrop Technologies Inc., Del. USA). 
4.3.7 Gene Expression  
Expression of HMVEC-L and BSMC 18S, intracellular adhesion molecule 
(ICAM-1), vascular cellular adhesion molecule (VCAM-1), and tumor necrosis alpha-
receptor 1 (TNFαR1) were measured via quantitative real-time PCR using an ABI 7300 
Real-Time PCR system (Applied Biosystems, Branchburg, NJ) with a TaqMan core 
reagent kit. All primers and probe sets were obtained from Applied Biosystems TaqMan 
Assays-on-Demand and utilized accordingly to manufacturers instructions. Pooled RNA 
from each cell type was serial-diluted in the range of 0.0156-50 ng and used to establish a 
standard curve; total RNA for each unknown samples was also diluted in this range. RT-
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PCR reactions were performed according to the instructions of the ABI Real-Time PCR 
system and TaqMan Real Time PCR Core Kit. Expression of each gene of interest was 
then normalized using the corresponding 18S quantification. Data for each gene is 
presented as a ratio of 18S.  
4.3.8 Laminar Flow Adhesion Assay 
BSMCs were cultured as previously described until approximately 90% confluent. 
Cells were then removed from the T-75 cm
2
 flask with trypsin (0.25%)/EDTA (0.1 µM), 
and centrifuged at 200 x g for 5 min. Cells were resuspended with 3 mL of cells culture 
media and counted using an improved Neubauer cell counting chamber with trypan blue 
staining to assess viability. Cells were seeded onto 40 mm glass coverslips at a final 
concentration of 2.5 x10
5
 cells/mL and incubated at 37°C, 5% CO2 for 12-24 hrs until 
approximately 90% confluent. Cells were washed 3 times with phosphate buffered saline 
(PBS) and fluorescently labeled with Calcein Am  (Invitrogen, Carlsbad, Ca)(1 µg/mL) 
for 30 min. at 37° C, 5% CO2. Afterwards, the coverslips were washed 3 times with PBS 
to remove excess Calcein AM. 
 U937 cells (monocyte line) were centrifuged at 200 x g for 5 minutes. Cells were 
resuspended in 3 mL of FBS free, phenol red free medium and counted as previously 
described. Viability of U937 cells was >90% for all assays. U937 cells were adjusted to a 
final concentration of 1.0 x 10
6
 cells/mL. The cells were fluorescently labeled with 1,1′-
Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI)(Sigma, St. Louis, 
MO) at a final concentration of 4.16 µg/mL for 20 min. at 37°C, 5% CO2. After labeling, 
the cells were topped off with FBS free, phenol red free RPMI 1640 medium and 
centrifuged at 200 x g for 10 minutes. The supernatant was removed and the labeled 
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U937 cells were resuspended with 3mL of either (vehicle, 0.5 mM leucine, 30 nM 
nitrendipine, 10 nM calcitriol or calcitriol and nitrendipine combination) adipocyte-
BSMC co-culture medium (1.0 x 10
6
 cells/mL final concentration) or by the same 
chemicals and concentrations diluted in RPMI 1640 medium for direct treatments.  
4.3.9 U937 Monocyte-BSMC Adhesion Assay 
This assay was modified from a previously described method (46). Briefly, a 
coverslip containing a monolayer of Calcein AM labeled BSMCs were assembled in a 
FCS2 microscopy stage mounted perfusion system (Bioptechs Inc, Butler, PA) containing 
0.5 mm gaskets. FBS free, phenol red free RPMI 1640 cell culture media (Gibco, Grand 
Island, NY) was perfused across the BSMC monolayer at a flow rate of 0.5 mL/min 
(shear rate=132.9 s
-1
) for 10 min. Afterwards, the pump was stopped and the affluent 
tubing was placed in a 12 x 75 mm tube containing the prepared U937 cells in adipocyte-
BSMC co-culture or directly supplemented media. The pump was restarted and ran for 
5.5 min., which was the optimized time to allow fluid to flow through the entire system to 
the effluent end. The pump was then stopped, and the effluent end of the tubing was 
placed back into the original 12 x 75 mm tube, allowing for a continuous, recycled 
perfusion. The pump was then restarted and ran for 1 hr. Afterwards, unbound U937 cells 
were washed off for 10 min with FBS-free, phenol red-free RPMI 1640 media. For 
comparative purposes, a perfusion with the control adipocyte-BSMC co-culture media 
was ran every day prior to running a perfusion with a given treatment group. This 
allowed for each treatment group perfusion (leucine, calcitriol, nitrendipine, or calcitriol 
and nitrendipine combination) to be normalized to the control adipocyte-BSMC co-
culture or vehicle direct supplemented media each day. 
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4.3.10 Microscopy and Image Analysis 
Microscopy was performed on a Nikon Eclipse Ti-E Epi-fluorescence microscope 
(Nikon Instruments Inc., Melville, NY) equipped with an automated stage and a 20 X 
objective. A 3 X 3 large image scan was taken in each of 5 random fields by multi-
channel capture (channel 1: excitation/emission=488/517 nm, channel 2: ex/em 550/567 
nm). Image analysis was performed using Nikon Elements 3.1 software (Nikon, Melville, 
NY). Binary thresholding was individually applied to both cell types to exclude non-
specific staining, generating a percent area occupied by fluorescence, which has been 
shown to be a direct correlation to the cell count (47). Results are presented as the ratio of 
percent area occupied by fluorescence (U937: BSMC). 
4.3.11 Phlebotomy 
Blood draws were approved from an ethical standpoint by the Institutional 
Review Board at the University of Tennessee (IRB #8961 B).  Subjects interested in 
donating blood were required to meet standard inclusion criteria guidelines that were out 
lined in the screening form. Blood was drawn using a 19-guage butterfly needle equipped 
with a vaccutainer connection and 10-30 mL of blood was collected each time into 
sodium heparin vaccutainer tubes (BD Biosciences; San Jose, CA).  Blood was 
immediately used for all assays described below. 
4.3.12 Whole Blood Leukocyte CD11b Expression by Flow Cytometry  
Whole blood samples were collected and 500 µl of each sample was placed into a 
2 mL eppendorf tube. Previously generated adipocyte CM (vehicle, leucine, calcitriol, 
leucine and calcitriol combination) in the amount of 500 µl was added to the 2 mL tube 
and incubated with the blood at 37°C, 5% CO2 for 1 or 2 hours. After incubation, the 
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whole blood and adipocyte CM mixture was fixed in 2% paraformaldehyde for 10 min. 
The tubes were then topped off with PBS and centrifuged at 200 X g for 5 min. Cell 
pellets were resuspended in 100 µl of primary labeling mixture containing 1 µg of mouse, 
anti-human CD11b monoclonal antibody (abcam, Cambridge, MA) diluted in 1 mL of 
PBS. The primary antibody was incubated at 25°C for 1 hr. The cells were washed with 
PBS and centrifuged as previously described.  A secondary antibody conjugated to 
Alexaflour 488 (1µg of goat, anti-mouse IgG ) (Jackson ImmunoResearch Laboratories, 
West Grove, PA) was diluted in 1 mL of PBS  and subsequently incubated with the cells 
for 30 min at 25°C. Cells were washed, centrifuged and resuspended in PBS. Flow 
cytometry was performed on an Accuri C6 Cytometer (Accuri, Ann Arbor, MI).  Twenty 
thousand events were collected and a marker gate was set on the isotypic control. The 
same gate was applied to the CD11b stained samples generating a percent of cells that are 
positive for CD11b expression. 
4.3.13 ICAM-1 or CD54 Expression Flow Cytometry 
HMVEC-Ls were cultured as previously described. Cells (1.5 x 10
5
) were seeded 
in each well of a 6 well plate and grown at 37°C, 5% CO2 for 24-48 hrs until 
approximately 90% confluent. HMVEC-L cells were washed with PBS and incubated 
with 2 mL of the various adipocyte CM (vehicle, leucine, calcitriol, leucine and calcitriol 
combination) for 48 hrs at 37°C, 5% CO2. After incubation, the cells were washed 3 
times with PBS and removed from the wells with trypsin (0.25%)/EDTA (0.1 µM). Cells 
were centrifuged at 250 X g for 5 min and resuspended in 2% paraformaldehyde for 10 
min fixation. The tubes were topped off with PBS and centrifuged as previously 
described. Cell pellets were resuspended in 100 µl of PBS and incubated with 1 µg of 
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mouse, anti-human CD54 monoclonal antibody (Beckman Coulter, Brea, CA) for 1 hr at 
25°C. Cells were washed with PBS and centrifuged as previously described. Cell pellets 
were resuspended in 100 µl of PBS and incubated with 1µg of goat, anti-mouse Alexa 
488 (IgG1) secondary antibody (Invitrogen, Grand Island, NY) for 45 min at 25°C. Cells 
were washed with PBS and centrifuged as previously described. Pellets were resuspended 
in 300 µl PBS and analyzed by flow cytometry as described above. 
4.3.14 Statistical Analysis 
Results are shown as mean (±SEM) values. Groups were compared by a one-way 
analysis of the variance of the means (One-way ANOVA). Data was tested for equal 
variances (Levene’s Test) and normality before ANOVA analysis. Differences among 
groups determined by Tukey’s HSD. A P value of less than 0.05 was regarded as 
indicative of a significant difference.  
4.4 Results 
4.4.1 ICAM-1/CD54 mRNA expression in HMVEC-L 
HMVEC-L cells were harvested and mRNA extracted following 48 hr. incubation 
with treated adipocyte CM.  ICAM-1 mRNA was normalized to 18S providing ICAM-
1/18S ratio that was compared among groups. Leucine CM treated endothelial cells had 
significantly reduced ICAM-1 mRNA levels compared to calcitriol CM treated cells 
(p<0.05). Leucine in combination with calcitriol CM significantly reduced the amount of 
ICAM-1 mRNA in HMVEC-L cells compared to lung endothelial cells treated with 




4.4.2 ICAM-1/CD54 protein expression in HMVEC-L via Flow Cytometry 
Calcitriol CM treated HMVEC-Ls had significantly higher levels of ICAM-1 
protein expression compared to control CM treated cells (p<0.05). Leucine CM treated 
lung endothelial cells, however, had significantly lower levels of ICAM-1 protein 
expression calcitriol CM treated (p<0.01) cells. The addition of leucine to calcitriol CM 
significantly reduced the levels of ICAM-1 protein expression compared to calcitriol CM 
treated cells alone (p<0.05) (Figure 2). 
4.4.3 Leukocyte Activation Marker CD11b Expression Using Flow Cytometry 
CD11b expression in leukocytes treated with calcitriol adipocyte CM were 
increased by approximately 67% compared to control adipocyte CM treated PMNC 
leukocytes (p<0.01) (Figure 3). Conversely, leucine adipocyte CM treated leukocytes 
were observed to have approximately a 40% reduction in CD11b expression compared to 
control (p<0.01). Upon the addition of leucine to the calcitriol adipocyte CM treated 
leukocytes there was a significant reduction in the protein expression of the activation 
integrin CD11b protein expression (p<0.05).  
4.4.4 Laminar Flow Adhesion Assay U937 Monocytes-BSMC Monolayer 
Calcitriol direct treatment, without adipocyte exposure, markedly increased 
adhesion of U937 monocytes to BSMC by approximately 7 fold, from 225 ± 14 to 1557 ± 
489 cells adhering/µm
2
 (p<0.001) (Table 4-1). Notably, this effect is not mediated by 
calcium signaling, as inhibition of Ca
2+ 
influx with nitrendipine did not reverse this 






Figure 4-1: Effects of various adipocyte CM on ICAM
Values are expressed as mean 
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Figure 4-2: Effects of various 
L cells. Values are expressed as mean 









adipocyte CM on ICAM-1 protein expression in HMVEC
± SEM, (n=6). * Significant different from control 





Figure 4-3: Figure 4-2: Effects of various adipocyte CM on CD11b protein expression in 
whole blood leukocytes. Values are expressed as mean 
different from control CM, (p < 0.05). **Significant
(p<0.05). 
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± SEM, (n=6). * Significant 
ly different from calcitriol CM, 
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Table 4-1: U937-BSMC Adherence (Direct Treatments) 
 
                                              Direct Treatment U937-BSMC Adherence   
Control 
0.5 mM  
Leucine 









225 ± 14 885 ± 1 1557 ± 489 1023 ± 141         2384 ± 247 
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fact resulted in further stimulation of adhesion. Nitrendipine increased monocyte 
adhesion to BSMCs  (p<0.05). The addition of a combined calcitriol and nitrendipine 
caused a significant increase in monocyte adhesion to BSMCs (p<0.01). There was also a 
slight increase in U937 monocyte adhesion to BSMCs with direct leucine treatment 
(p<0.05). 
Adipocyte-BSMC co-culture studies demonstrate a similar effect of calcitriol on 
adherence (p<0.05), but in contrast to the direct effects of the chemical treatments, 
leucine treatment resulted in an approximate 50% reduction in adhesion of U937 human 
monocytes to BSMCs (p<0.001). Similar to the direct effects of the chemical treatments, 
nitrendipine exerted no effect, indicating the observed effects of calcitriol are not 
mediated by Ca
2+
 signaling. The data are summarized in Figure 4 A&B (direct) and 
Figure 5 (adipocyte-BSMC co-culture). 
4.5 Discussion 
Leucine and calcitriol adipocyte CM appear to have opposing effects on leukocyte 
activation as measured by CD11b, ICAM-1 protein expression, and monocyte-BSMC 
adhesion. Adhesion molecule protein expression of ICAM-1 was increased by calcitriol 
CM treatment of HMVEC-Ls whilst leucine decreases this effect compared to control. 
Leucine CM appears to initiate an anti-inflammatory response in leukocytes as indicated 
by the reduction in the CD11b activation marker compared to control. On the contrary, 
calcitriol adipocyte CM increased leukocyte activation indicated by the significant 

























Figure 4-4 B. U937 cells per micrometer squared area on BSMC monolayer observed 
with the various direct chemical treatments.















Figure 4-5: U937 cells per micrometer
with adipocyte co-culture conditions.
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appear to ameliorate these effects of calcitriol as shown by the decrease in leukocyte 
CD11b expression when adipocyte CM contained both calcitriol and leucine versus 
calcitriol alone. 
From previous studies, we know that leucine treatment of adipocytes increases the 
anti-inflammatory adiponectin and decreases the pro-inflammatory TNFα (37-45).  
However, the exact mechanism of how leucine adipocyte CM decreases adhesion 
molecule expression, leukocyte integrin expression, and subsequent adhesion is unclear. 
Leucine, when applied directly to U937 monocytes and BSMCs, increased leukocyte 
adhesion. While this appears counterintuitive based on our hypothesis, it is important to 
emphasize that this is a direct effect of leucine (no exposure to adipocyte metabolism), 
while the more physiologically relevant effect is found in the co-culture experiment 
where monocytes and BSMCs were exposed to adipocyte CM. It is likely that the 
differences in adipocyte cytokine production among the various treatments (control, 
leucine, calcitriol) are responsible for these functional responses. The data from this study 
suggest that leucine could attenuate leukocyte activation, adhesion molecule expression, 
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Leucine and calcium supplemented high fat diets 


























The increase in inflammatory cytokines observed in obesity may link excess 
adiposity to asthmatic airway inflammation. We have previously demonstrated that 1, 25 
dihydroxycholecalciferol (calcitriol) and leucine modulate adipocyte and macrophage 
inflammatory cytokine production. Since, several of these cytokines are also involved in 
asthmatic disease, we sought to determine if high fat diets supplemented with calcium, 
leucine, or both would alter airway inflammation in an established murine model of 
asthma. Diet-induced obese female BALB/c mice sensitized and challenged with 
ovalbumin (OVA) were fed high fat diets with no supplementation, high dose calcium 
(1.2%), leucine (24g/kg; 200% normal level), or calcium (1.2%) in combination with 
leucine (24g/kg; 200% normal level) over a six-week period. Mice fed a diet 
supplemented with calcium and leucine exhibited a significant decrease in eosinophil 
leukocytes present in lung bronchoalveolar lavage fluid (BALF) as compared to control 
diet animals (p<0.05). Our data suggests that calcium and leucine may provide a 
synergistic attenuation of lung leukocyte infiltration and subsequent airway inflammation 
in obesity-associated asthma. 
5.2 Introduction 
Asthma and obesity have increased in prevalence over the past thirty years in a 
parallel fashion (1-4). Epidemiological, longitudinal, and prospective studies suggest that 
the positive relationship between obesity and asthma may be a casual one (5-8). 
However, the mechanistic link between the two is still elusive. As asthma and obesity 
share many of the same inflammatory cytokines and oxidative stress markers a likely 
connection may be immunological (9-11). It is widely acknowledged that chronic low-
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grade systemic inflammation is a hallmark of obesity and this inflammation along with 
oxidative stress may work synergistically to adversely modify the airways (11-19). 
Oxidative stress alters the balance of inflammatory and anti-inflammatory cytokines 
secreted by adipose tissue. Increased reactive oxygen species (ROS) suppresses adipose 
tissue expression of adiponectin and increases expression of inflammatory factors, 
including TNFα (20), while suppression of ROS exerts the opposite effect. Adipose tissue 
is a significant contributor to systemic oxidative stress. Our lab and others have shown 
adipocyte ROS production to be modulated by mitochondrial uncoupling status and 
cytosolic Ca
2+
 signaling, both of which are regulated by calcitriol (1,25 
dihydroxycholecalciferol) in murine and human adipocytes (21-23). Calcitriol (elevated 
in calcium deficiency and obesity) suppresses expression of adipocyte uncoupling protein 
2 (UCP2), resulting in greater mitochondrial membrane potential, and stimulates 
cytosolic Ca
2+ 
signaling, both of which lead to increased ROS production (21-24). We 
have recently shown that calcitriol dose-dependently stimulates ROS production in 
murine and human adipocytes and concomitantly stimulates the expression and secretion 
of inflammatory cytokines, including TNFα, while inhibiting adiponectin expression and 
secretion (21-24). Consequently, we evaluated the ability of dietary calcium-induced 
suppression of circulating calcitriol to attenuate oxidative and inflammatory stress and 
found significant suppression of both adipose tissue and systemic oxidative and 
inflammatory stress in a mouse model (21, 25). Data from these studies also support a 
role of the branched chain amino acid leucine in attenuating oxidative and inflammatory 
stress (26, 27). Leucine was shown to stimulate mitochondrial biogenesis, oxygen 
consumption and fatty acid oxidation in adipocytes and muscle cells (26, 27). The 
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increased energy utilization due to leucine treatment in these cell types resulted in 
reduced oxidative and inflammatory stress that otherwise would result from nutrient 
overload and obesity (26, 27). Consequently, we postulated that dietary calcium and 
leucine would exert synergistic and beneficial effects on adipocyte cytokine secretion in 
diet induced obese mice leading to attenuation of airway inflammation in a murine model 
of asthma. 
5.3 Materials and Methods 
5.3.1 Animals and Diets 
Six week old female BALB/c mice (Harlan Laboratories, Indianapolis, IN) were 
fed a high fat-diet (fat increased to 45% of energy) to induce obesity (Research Diets 
D12451) (Table 5-1) with either no supplementation (Control Diet), calcium raised to 
1.2% (High Calcium Diet), leucine 24g/kg; 200% of normal level (Leucine Diet), or the 
combination of the calcium 1.2% and leucine 24g/kg (High Calcium and Leucine Diet). 
Animals were divided into two phases (Table 5-2 A-D) (40 animals in each) and were 
randomly assigned to one of the four diets on either two days before the first 
intraperitoneal (i.p.) injection (prevention phase) or were fed Control diets before being 
randomly assigned to stay on Control diet or move to a supplemented diet on Day 10 
(treatment phase). Within each phase and each diet the animals were divided so that OVA 
allergic airway inflammation would sensitize half of the mice and the other mice would 

























(HC + L) 
 (1.2% Ca) 
Ingredient (gm)     
Casein, 80 Mesh 200 200 200 200 
L-Cystine 3 3 3 3 
L-Leucine 0 0 18 18 
Corn Starch 72.8 72.8 72.8 72.8 
















Soybean oil 25 25 25 25 
Lard 177.5 177.5 177.5 177.5 
Mineral Mix S10026 10 10 10 10 
Calcium Carbonate 10 30 10 30 
Potassium Citrate 6.2 6.2 6.2 6.2 
Potassium Phosphate 13 13 13 13 
 









Choline Bitartrate 2 2 2 2 
Macronutrients (gm/kg diet) 
Protein 203 203 203 203 
Carbohydrate 355 355 355 355 
Fat 203 203 203 203 
Fiber 50 50 50 50 
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High Ca +  
Leucine 200%  
(HC + L) 
(1.2% Ca) 
Macronutrients (kcal/kg diet) 
Protein 811 811 811 811 
Carbohydrate 1420 1420 1420 1420 
Fat 1826 1826 1826 1826 
Total 4057 4057 4057 4057 
 
Macronutrients (kcal%) 
Protein 20 20 20 20 
Carbohydrate 35 35 35 35 
Fat 45 45 45 45 
Total 100 100 100 100 
Calcium, gm 4.0 12.0 4.0 12 
Phosphorus, gm 4.57 4.57 4.57 4.57 



























Table 5-2 A: Prevention Phase Group A (OVA) 
 














+Leucine Diet  
(HC + L) 
n=5 
     
Assigned Diet  
(2 days before i.p.) 
 
Control HC Leucine HC + L 
i.p. Injections  
(Day 0, 4, 7) 
 
OVA OVA OVA OVA 
Aerosol Challenges 
(Day 12–47) 
OVA OVA OVA OVA 
Sacrifice Day 48 Day 48 Day 48 Day 48 
Sample Size 5 5 5 5 
 
 
Table 5-2 B: Prevention Phase Group B (PBS) 
 














+Leucine Diet  
(HC + L) 
n=5 
     
Assigned Diet  
(2 days before i.p.) 
 
Control HC Leucine HC + L 
 i.p. Injections  
(Day 0, 4, 7) 
 




PBS PBS PBS PBS 
Sacrifice 
 
Day 48 Day 48 Day 48 Day 48 




Table 5-2 C: Treatment Phase Group C (OVA) 
 













     
Assigned Diet  
(2 days before i.p.) 
Control Control Control Control 
  
i.p. Injections  

























OVA OVA OVA OVA 
Sacrifice Day 48 Day 48 Day 48 Day 48 
Sample Size 5 5 5 5 
 
Table 5.2 D: Treatment Phase Group D (PBS) 
 













     
Assigned Diet  
(2 days before i.p.) 
Control Control Control Control 
  
i.p. Injections  

























PBS PBS PBS PBS 
Sacrifice Day 48 Day 48 Day 48 Day 48 
Sample Size 5 5 5 5 
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C and regime of 12 h light/dark 
cycle. The animals had free access to water and their experimental food throughout the 
study. All animals were checked daily for any signs of disease or death and moribund 
animals (as defined by the facility veterinarian) were humanely euthanized. Weight was 
measured to the nearest gram at the beginning of the experiment and then weekly until 
the end of the study. At the end of the study (~7 weeks) all animals were humanely 
euthanized by administration of sodium pentobarbital and subsequent exsanguination by 
severing the vena cava. Blood was immediately collected from the vena cava supply, 
allowed to clot at room temperature, and centrifuged to obtain serum. Immediately after 
euthanasia, bronchoalveolar lavage (BAL) was performed and the lungs were harvested. 
The left lung was fixed in 4% formalin for subsequent H&E staining and the right lung 
was flash frozen in liquid nitrogen for later experiments. 
This study and all animal procedures were performed under the auspices of a 
University of Tennessee Institutional Animal Care and Use Committee-approved 
protocol and in accordance with PHS policy and recommendation of the Guide. 
5.3.2 Induction of Allergic Airway Inflammation 
The sensitization protocol was started at six weeks of age (Day 0 of the study 
protocol). Briefly, half the animals in both phases (prevention and treatment)  (n=40 
total) were sensitized with 50-µg i.p. injections of chicken egg albumin (ovalbumin 
[OVA]; Grad V, Sigma-Aldrich, St. Louis, MO, USA) dissolved in 0.1 mL sterile 
phosphate buffered saline (PBS) on Days 0, 4, and 7 (28).  Starting on Day 12, animals 
were challenged by aerosol nebulization delivery of ovalbumin. Animals were exposed to 
a solution of 2.5% OVA dissolved in PBS aerosolized by delivery of compressed air to a 
nebulizer for 30 min/day, 3 days/week (to allow at least a day in between each challenge) 
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from Day 12 to Day 47 (29). Non-sensitized or control animals for the disease model 
from both phases (n=40) were subjected to the exact same procedures on the same days 
but were not exposed to OVA. Instead PBS alone served as vehicle for the i.p. injections 
as well as nebulization deliveries. 
5.3.3 Bronchial Alveolar Lavage Fluid (BALF) and Serum 
Lungs were lavaged twice with 1 mL of cold PBS and the lavagates were pooled 
and placed on ice until centrifuged at 400 x g at 4
°
C for 10 min. Supernatant was 
collected and stored at -80
°
C for later experiments. Cell pellets were resuspended in 
Hank’s Balanced Salt solution and an Advia 120 hematology system (Siemens 
Healthcare, Tarrytown, NY) was used to assess the total number of cells and estimate 
leukocyte distributions. Aliquots of cells were also centrifuged onto glass slides at 800 
rpm for 10 min by an Aerospray 7120 cytocentrifuge (Wescor, Inc. Logan, UT). These 
slides were air-dried, and then stained with a methanolic Wright’s stain using the 
AerosprayPro 7151 (Wescor, Inc. Logan, UT). Cell differentials were determined by 
counting 300 cells under 400X magnification by a certified pathologist in the veterinary 
diagnostic pathology lab at the University of Tennessee Knoxville School of Veterinary 
Medicine. Blood was collected from the severing of the vena cava. Serum was isolated by 
allowing blood to clot at room temperature and subsequent centrifugation. These 
protocols were adapted from those described by Williams et al (30).  
5.3.4 Staining Lung Tissue Sections 
Lung lobes were fixed in 4% formalin and paraffin embedded. These lung 
sections were stained with haematoxylin and eosin following manufacturer’s 
recommendation (Newcomer Supply, Middleton, WI, USA). Stained lung sections were 
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then scored by degree of epithelial hyperplasia height to assess inflammation. The 
University of Tennessee-Knoxville attending veterinarian determined epithelial 
hyperplasia scores.  
5.3.5 Epithelial Hyperplasia in the Lung (HypEpi) 
Epithelial hyperplasia is characteristic of the initial stages of airway remodeling 
and indicates inflammation and the onset of asthmatic disease. Epithelial hyperplasia was 
pathologically assessed by a score of 0=absent of hyperplasia, 1=twice normal height, 
2=three times normal height, 3=four times normal height. The higher the score indicates 
the higher degree of inflammation and airway remodeling.  
5.3.6 Inducible Bronchus-Associated Lymphoid Tissue (iBALT) 
Inflammation in the lung facilitates the emergence of ectopic lymphoid tissue 
termed inducible bronchus-associated lymphoid tissue (iBALT). This tissue can be found 
throughout the lung when inflammation or infections are present (31). Here we used the 
degree of iBALT present in the lungs of the study mice to assess lung inflammation. 
Bronchial associated lymphoid tissue was scored as 0=normal or no inducible lymphoid 
tissue present, 1= present around bronchi and larger bronchioles, 2= present around 
smaller bronchioles, 3= more around smaller bronchioles, by the attending veterinarian at 
the University of Tennessee Knoxville. 
5.3.7 Statistical Analysis 
Results are shown as mean (±SEM) values. Comparison of means between all diet 
groups was performed by one-way ANOVA. Before one-way ANOVA data was tested 
for equal variances (Levene’s test) and normality. Differences among means were 
assessed by Tukey’s HSD. Student’s t test was used to test for weight gain differences 
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between (OVA) and (PBS) animals in both phases within diet groups. A P value of less 
than 0.05 was regarded as indicative of a significant difference. Chi-squared was used to 
assess categorical data (pathological degree scoring) and a value of less than 0.05 was 
regarded as indicative of a significant difference. 
5.4 Results 
There were significantly (p<0.05) more polymorphonuclear cell leukocytes 
(PMNs) including eosinophils and neutrophils present in the bronchoaveolar lavage fluid 
(BALF) of the OVA animals versus the PBS animals. There was also a much higher 
degree of inflammation in the lungs of OVA-sensitized and challenged animals as scored 
by inducible bronchus associated lymphoid tissue as compared to PBS vehicle animals 
(Table 5-3). Further, the degree of epithelial hyperplasia was increased in OVA 
challenged animals as compared to PBS challenged animals (Table 5-3). There were no 
significant differences in weight gain throughout the study or abdominal fat between diet 
groups in OVA or PBS treated animals. However, prevention phase animals treated with 
(OVA) gained significantly less weight throughout the study than (PBS) animals in all 
diet groups (p<0.01) (Figure 1). The same trend was observed in the treatment phase 
although the only significant difference was observed in leucine diet animals  (p<0.05) 
(Figure 2). Prevention phase Group A OVA treated animals fed the combined high 
calcium and leucine diet had significantly fewer eosinophils present in BALF when 
compared to control diets (p<0.05) (Figure 3A). However, there no significant differences 
in neutrophils present in the BALF of Group A (OVA) animals between diets. Treatment 
phase Group C (OVA) animals showed no significant differences in the eosinophils
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Table 5-3: Pathology Scores of Lung iBALT and HypEpi Across Study 
 



















1.0952 0 1.3182 0.0238 
PBS animals had significantly less 
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PBS animals had significantly less 










Figure 5-1: Prevention Phase Weight Gain Group A (OVA) vs. Group B (PBS) Animals. 
Values are expressed as mean 
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± SEM, (n=6). *Significantly different from same diet in 










Figure 5-2: Treatment Phase Weight Gain Group C (OVA) vs Group D (PBS).
expressed as mean ± SEM, (n=5). *Significant
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Figure 5-3 A: Group A (OVA) BALF Percentage of 










Eosinophils. Values are expressed as 
ly different from control CM, (p < 0.05). 
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present in BALF between diets (Figure 3B). Neutrophils present in BALF collected from 
treatment phase Group C (OVA) animals were reduced in the high calcium versus control 
diet, although this difference only approached significance (p<0.07) (Figure 4). Inducible 
bronchus associated lymphoid tissue (iBALT) (Figure 5) and lung epithelial hyperplasia 
(HypEpi) (Figure 6) and (Figure 7) as indicators of inflammation and airway remodeling 
were not significantly different across diets. However, the control diet animals had the 
largest percentage (33.3%) of iBALT scores in the severe category, while 40% of the 
High Calcium + Leucine diet animals were scored in the minimal to no iBALT category 
and none were scored in the severe category. 
Serum adiponectin levels measured in prevention phase animals were not 
significantly different between diets (Figure 8). OVA treated animals (Group A) serum 
adiponectin level was significantly higher (p<0.01) than PBS (Group B) animals. 
5.5 Discussion 
Calcium and leucine supplementation of high fat diets were found to have only a 
modest influence on airway inflammation in a murine model of asthma. A more 
prominent result was expected based on previous studies where a significant reduction of 
inflammatory and oxidative stress was achieved in obese mice by similar interventions 
(21, 25). The reduction in obesity-induced inflammation observed in these studies was at 
least in part due to the increase of the anti-inflammatory adiponectin and decrease of pro-
inflammatory TNFα secretion from adipose tissue. Studies where comparable asthma 
models were utilized such as Shore et al (32) showed significant improvement of disease 
symptoms with the exogenous administration of adiponectin. Medoff et al (28) further 
supported the role of adiponectin in asthmatic disease and Blacquiere et al (33) was 
 
helpful in deciding sample size estimates for our female BALB/c model. Serum 
adiponectin levels were not significantly different in this study despite our previous 
studies where adiponectin levels were significantly changed with dietary intervention. 
Figure 5-3 B: Group C (OVA) BALF Percentage of Eosinophils.
















Figure 5-4:Group C (OVA) BALF Percentages of Neutrophils. Values are expressed as 






































Table 5-4: Group A (OVA) Pathology Scores iBALT 
 
Group A (OVA) Pathology Scores iBALT  
Control Hi Ca Leucine Hi Ca + Leucine Comment 
Severe 
(2.0) 
33.33% 0% 20% 0% 
Control diet animals had the largest 




66.667% 100% 80% 60% 
High calcium diet animals contained all 
their scores in the Moderate category 
Minimal 
(0.0-0.5) 
0% 0% 0% 40% 
Almost half of the Hi Ca +Leucine diet 
animals were scored in the minimal to 







Table 5-5: Group C (OVA) Pathology Scores iBALT 
 
Group C (OVA) Pathology Scores iBALT  
Control Leucine Hi Ca Hi Ca + Leucine Comment 
Severe 
(2.0) 
33.33% 20% 60% 16.667% 
High Calcium diet animals had the 
most scores in the Severe category 
Moderate 
(1.5) 
 0% 0% 0% 33.33% 
The group with highest percentage of 
animals with Moderate iBALT were 
fed the Hi Ca + L diet 
Mild 
(1.0) 
50% 60% 40% 50% 
Almost half of all the animals in each 
diet group scored in the Mild category 
Minimal 
(0.0-0.5) 
16.6667% 20% 0% 0% 
Leucine diet animals had the highest 
percentage in the Minimal category 
followed by Control diet animals 
 
 
































































Score of Epithelial Hyperplasia in Comparison to normal lung 























































































Figure 5-7: Prevention Phase Group A (OVA) and Group B (PBS) 
measured in collected serum.

























However, in this study it is likely that the subtle dietary interventions used to 
increase endogenous adiponectin secretion may have been more pronounced in a larger 
sample size and longer study duration. Serum adiponectin levels in prevention phase 
OVA animals were significantly higher than PBS animals (p<0.01). The higher 
adiponectin levels in Group A OVA compared to Group B PBS animals reflects the 
observation that OVA animals also weighed significantly less than PBS animals. 
Treatment phase animals did not yield the same results as prevention phase animals, 
which suggests that experimental diet exposure time significantly impacted results. 
Accordingly, (BALF) neutrophils in treatment phase OVA animals fed high calcium diets 
appeared reduced compared to control diet animals and though not significant it was a 
trend not observed in prevention phase subjects. Also, in prevention phase all OVA 
treated animals gained significantly less weight than their PBS counterparts (p<0.01) but 
this trend was not significant in treatment phase animals with the exception of leucine 
diet mice (p<0.05).     
Our previous studies were conducted in aP2-agouti transgenic mice that are 
genetically predisposed to develop obesity but were not an appropriate model for asthma 
(21). The current study was conducted in BALB/c mice; although this is an established 
asthma model, BALB/c mice are lean, making it difficult to use in the study of dietary 
modulation of airway function in obesity. By introducing high fat diets to BALB/c mice 
we anticipated the generation of excess adiposity to produce an asthma model 
incorporating characteristics of obesity. The combination of a mixed disease model, 
sample size/power, and duration of the study may have hindered hypothesized results. 
Still, high calcium and leucine-supplemented diets were able to significantly reduce the 
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amount of eosinophils present in BALF of prevention phase OVA animals compared to 
control diet mice. This decrease may have contributed to the lower pathological scores of 
lung inflammation (iBALT) and airway remodeling (HypEpi) found in this group 
compared to control diet animals although these trends were not significant. Results from 
this study give only a modest indication of the potential of calcium and leucine in 
attenuating obesity associated airway inflammation further research in this area is still 
warranted. 
5.6 Strengths, Weaknesses, and Limitations 
The strength of this study is the generation a murine asthma model with lower 
airway inflammation. Additionally, the BALB/c mouse strain is the ideal model for 
translational asthma studies. However, the model is also a limitation as a lean mice strain 
it is difficult to use in dietary modulation of airway function of obesity studies. For this 
reason the BALB/c mouse model is both a strength (asthma) and a limitation (obesity) of 
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Leucine and calcitriol appear to have opposing effects on adipocyte pro-
inflammatory cytokine secretion. Experiments conducted in vitro suggest that leucine 
provided an anti-inflammatory effect by decreasing leukocyte activation markers 
(CD11b), decreasing adhesion molecule expression (ICAM-1), and subsequently 
decreasing leukocyte adhesion to smooth muscle cells and endothelial cells. Extension of 
these findings to an established murine model of asthma did result in a significant 
decrease in eosinophils present in the bronchoalveolar lavage fluid (BALF) of BALB/c 
mice fed a high calcium and leucine supplemented high fat diet compared to control diet 
animals. Overall, however the animal study showed only modest effects of calcium and 
leucine supplementation. The BALB/c mice strain (although ideal for asthma studies) is 
lean, making high-fat diet induced obesity difficult and perhaps compromising the 
desired model for this study. The prominent eosinophilic rich inflammation assessed by 
collected BALF fluid as opposed neutrophilic inflammation suggests the obesity 
associated asthmatic phenotype was not achieved in the BALB/c model. Nonetheless, 
calcium and leucine supplementation did decrease eosinophil infiltration likely a result 
decreased of leukocyte CD11b and lung endothelial cell ICAM-1 expression observed in 
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